

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07K 14/54		A1	(11) International Publication Number: WO 99/09063 (43) International Publication Date: 25 February 1999 (25.02.99)															
<p>(21) International Application Number: PCT/IL98/00379</p> <p>(22) International Filing Date: 13 August 1998 (13.08.98)</p> <p>(30) Priority Data:</p> <table> <tr><td>121554</td><td>14 August 1997 (14.08.97)</td><td>IL</td></tr> <tr><td>121639</td><td>27 August 1997 (27.08.97)</td><td>IL</td></tr> <tr><td>121860</td><td>29 September 1997 (29.09.97)</td><td>IL</td></tr> <tr><td>122134</td><td>6 November 1997 (06.11.97)</td><td>IL</td></tr> <tr><td>125463</td><td>22 July 1998 (22.07.98)</td><td>IL</td></tr> </table>		121554	14 August 1997 (14.08.97)	IL	121639	27 August 1997 (27.08.97)	IL	121860	29 September 1997 (29.09.97)	IL	122134	6 November 1997 (06.11.97)	IL	125463	22 July 1998 (22.07.98)	IL	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p>	
121554	14 August 1997 (14.08.97)	IL																
121639	27 August 1997 (27.08.97)	IL																
121860	29 September 1997 (29.09.97)	IL																
122134	6 November 1997 (06.11.97)	IL																
125463	22 July 1998 (22.07.98)	IL																
<p>(71) Applicant (<i>for all designated States except US</i>): YEDA RESEARCH AND DEVELOPMENT CO. LTD. [IL/IL]; Weizmann Institute of Science, P.O. Box 95, 76100 Rehovot (IL).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): NOVICK, Daniela [IL/IL]; Hanassi Harishon 40, 76302 Rehovot (IL). DINARELLO, Charles [US/US]; 333 15th Street, Boulder, CO 80302 (US). RUBINSTEIN, Menachem [IL/IL]; 16 Hatomer Street, 54042 Givat Shmuel (IL). KIM, Soo, Hyun [KR/IL]; Hamaapil Street 4, 76348 Rehovot (IL).</p> <p>(74) Agent: EINAV, Henry; Inter-Lab Ltd., Science-based Industrial Park, Kiryat Weizmann, 76110 Ness-Ziona (IL).</p>		<p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>																

(54) Title: INTERLEUKIN-18 BINDING PROTEINS, THEIR PREPARATION AND USE

(57) Abstract

Interleukin-18 binding proteins which are capable of binding IL-18 and/or modulating and/or blocking IL-18 activity are provided. Methods for their isolation and recombinant production, DNAs encoding them, DNA vectors expressing them, vectors useful for their expression in humans and other mammals, antibodies against them are also provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERLEUKIN-18 BINDING PROTEINS,THEIR PREPARATION AND USEField of the Invention

5 The present invention relates to interleukin-18 (IL-18) binding protein, hereinafter IL-18BP, capable of binding IL-18. More particularly, this invention relates to a soluble IL-18BP obtainable from body fluids, to soluble IL-18BPs obtainable by expression of suitable DNA vectors in host cells, to virus-encoded homologues of IL-18BP obtainable by expression of suitable DNA vectors in host cells, to vectors expressing the various IL-18BPs,
10 to vectors useful for expression of IL-18BP in humans and other mammals, to antibodies against IL-18BPs, to therapeutic use of said IL-18BPs by modulating and/or blocking IL-18 activity, to therapeutic use of said expression vectors in modulating and/or blocking IL-18 activity and to use of the antibodies.

Background of the Invention

15 In 1989, an endotoxin-induced serum activity that induced interferon- γ (IFN- γ) obtained from mouse spleen cells was described (27). This serum activity functioned not as a direct inducer of IFN- γ but rather as a co-stimulant together with IL-2 or mitogens. An attempt to purify the activity from post-endotoxin mouse serum revealed an apparently homogeneous 50-55 kDa protein (26). Since other cytokines can act as co-stimulants for
20 IFN- γ production, the failure of neutralizing antibodies to IL-1, IL-4, IL-5, IL-6, or TNF to neutralize the serum activity suggested it was a distinct factor. In 1995, the same scientists demonstrated that the endotoxin-induced co-stimulant for IFN- γ production was present in extracts of livers from mice preconditioned with *P. acnes* (31). In this model, the hepatic macrophage population (Kupffer cells) expand and in these mice, a low dose of bacterial
25 lipopolysaccharide (LPS), which in non-preconditioned mice is not lethal, becomes lethal. The factor, named IFN- γ -inducing factor (IGIF) and later designated interleukin-18 (IL-18), was purified to homogeneity from 1,200 grams of *P. acnes*-treated mouse livers. Degenerate oligonucleotides derived from amino acid sequences of purified IL-18 were used to clone a

murine IL-18 cDNA (31). IL-18 is an 18-19 kDa protein of 157 amino acids, which has no obvious similarities to any peptide in the databases. Messenger RNAs for IL-18 and interleukin-12 (IL-12) are readily detected in Kupffer cells and activated macrophages. Recombinant IL-18 induces IFN-gamma more potently than does IL-12, apparently through a separate pathway (31). Similar to the endotoxin-induced serum activity, IL-18 does not induce IFN- γ by itself, but functions primarily as a co-stimulant with mitogens or IL-2. IL-18 enhances T cell proliferation, apparently through an IL-2-dependent pathway, and enhances Th1 cytokine production *in vitro* and exhibits synergism when combined with IL-12 in terms of enhanced IFN- γ production (24).

Neutralizing antibodies to mouse IL-18 were shown to prevent the lethality of low-dose LPS in *P. acnes* pre-conditioned mice. Others had reported the importance of IFN- γ as a mediator of LPS lethality in pre-conditioned mice. For example, neutralizing anti-IFN- γ antibodies protected mice against Shwartzman-like shock (16), and galactosamine-treated mice deficient in the IFN- γ receptor were resistant to LPS-induced death (7). Hence, it was not unexpected that neutralizing antibodies to murine IL-18 protected *P. acnes*-preconditioned mice against lethal LPS (31). Anti-murine IL-18 treatment also protected surviving mice against severe hepatic cytotoxicity.

After the murine form was cloned, the human cDNA sequence for IL-18 was reported in 1996 (38). Recombinant human IL-18 exhibits natural IL-18 activity (38). Human recombinant IL-18 is without direct IFN- γ -inducing activity on human T-cells, but acts as a co-stimulant for production of IFN- γ and other T-helper cell-1 (Th1) cytokines (38). To date, IL-18 is thought of primarily as a co-stimulant for Th1 cytokine production (IFN- γ , IL-2 and granulocyte-macrophage colony stimulating factor) (20) and also as a co-stimulant for FAS ligand-mediated cytotoxicity of murine natural killer cell clones (37).

By cloning IL-18 from affected tissues and studying IL-18 gene expression, a close association of this cytokine with an autoimmune disease was found. The non-obese diabetic (NOD) mouse spontaneously develops autoimmune insulitis and diabetes, which can be accelerated and synchronized by a single injection of cyclophosphamide. IL-18 mRNA was demonstrated by reverse transcriptase PCR in NOD mouse pancreas during early stages of insulitis. Levels of IL-18 mRNA increased rapidly after cyclophosphamide treatment and

preceded a rise in IFN- γ mRNA, and subsequently diabetes. Interestingly, these kinetics mimic that of IL-12-p40 mRNA, resulting in a close correlation of individual mRNA levels. Cloning of the IL-18 cDNA from pancreas RNA followed by sequencing revealed identity with the IL-18 sequence cloned from Kupffer cells and in vivo pre-activated macrophages.

5 Also NOD mouse macrophages responded to cyclophosphamide with IL-18 gene expression while macrophages from Balb/c mice treated in parallel did not. Therefore, IL-18 expression is abnormally regulated in autoimmune NOD mice and closely associated with diabetes development (32).

IL-18 plays a potential role in immunoregulation or in inflammation by augmenting 10 the functional activity of Fas ligand on Th1 cells (10). IL-18 is also expressed in the adrenal cortex and therefore might be a secreted neuro-immunomodulator, playing an important role in orchestrating the immune system following a stressful experience (9).

In vivo, IL-18 is formed by cleavage of pro-IL-18, and its endogenous activity appears to account for IFN- γ production in P. acnes and LPS-mediated lethality. Because of 15 its activity, blocking the biological activity of IL-18 in human disease is a therapeutic strategy in many diseases. This can be accomplished using soluble receptors or blocking antibodies to the cell-bound IL-18 receptor.

Cytokine binding proteins (soluble cytokine receptors) correspond to the extracellular 20 ligand binding domains of their respective cell surface cytokine receptors. They are derived either by alternative splicing of a pre-mRNA, common to the cell surface receptor, or by proteolytic cleavage of the cell surface receptor. Such soluble receptors have been described in the past, including among others, the soluble receptors of IL-6 and IFN- γ (30), TNF (11, 12), IL-1 and IL-4 (21), IFN- α/β (28, 29) and others. One cytokine-binding protein, named osteoprotegerin (OPG, also known as osteoclast inhibitory factor - OCIF), a member of the 25 TNFR/Fas family, appears to be the first example of a soluble receptor that exists only as a secreted protein (1, 34, 39).

Summary of the Invention

The present invention provides IL-18 binding proteins (IL-18BPs) and virally 30 encoded IL-18BP homologues (hereinafter, viral IL-18BPs), and fused proteins, muteins, functional derivatives, active fragments and circularly permuted derivatives thereof,

capable of binding to IL-18. The invention also provides a process for isolating IL-18BPs from human fluids, and a process to obtain them by recombinant means. The invention also provides expression vectors of IL-18BPs, suitable for expression of IL-18BP in humans and other mammals. Specific IL-18BPs, virally encoded IL-18BP homologues, fused proteins, 5 muteins, functional derivatives, active fragments and circularly permuted derivatives thereof of the present invention are useful for modulating and/or blocking the biological activities of IL-18.

Replicable expression vehicles containing DNAs suitable for expression of the various IL-18BPs in host cells, host cells transformed herewith and proteins and polypeptides 10 produced by expression of such hosts are also provided.

The invention further provides pharmaceutical compositions consisting of suitable vehicles and IL-18BPs, or viral IL-18BPs, or vectors for expressing same in humans and other mammals, for the treatment of diseases or conditions which require modulation or blocking of IL-18 activity.

15 The invention further provides antibodies to the IL-18BPs and the viral IL-18BPs, suitable for affinity purification and immunoassays of same.

Description of the Figures

Figure 1 shows SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel 20 electrophoresis) of ligand affinity purified IL-18 binding protein. Crude urinary proteins (concentrated by ultrafiltration of 500 L normal human urine) were loaded on an IL-18-agarose column. The column was washed and bound proteins eluted at pH 2.2. Eluted fractions were neutralized and aliquots were analyzed by SDS-PAGE (10% acrylamide) under non-reducing conditions and silver staining. The lanes are: 1: crude urinary proteins 25 (1.5 µg, loaded on the gel); 2-9: elutions 1-8, respectively, from the IL-18-agarose column; 10: molecular weight markers, in kD, as indicated on the right side. An arrow indicates the band corresponding to IL-18BP.

Figure 2 shows an autoradiogram of SDS-PAGE (7.5 % acrylamide) of complexes 30 consisting of ^{125}I -IL-18 (apparent molecular weight 19 kD), cross-linked to the following

preparations of soluble IL-18 binding protein: Lane 1: Wash of the IL-18 affinity column. Lane 2: Elution 2 of the IL-18 affinity column. Lane 3: Elution 3 of the IL-18 affinity column. Molecular weight markers are indicated on the right side (in kD). An arrow indicates the cross-linked product (58 kD).

5

Figure 3 shows inhibition of IL-18-induced production of IFN- γ by IL-18BP

(A) Mouse splenocytes were stimulated (24 hr, 37°C) with the indicated combinations of LPS (1 μ g/ml) and human IL-18 (5 ng/ml), added either directly, or after pre-mixing (1 h, 37°C) with urinary IL-18BP. The level of muIFN- γ in the culture was determined after 24 hr.

10 (B) Mouse splenocytes were incubated (24 h) with LPS (1 μ g/ml) together with murine IL-18 (10 ng/ml) pre-mixed (1 h, 37°C) with increasing concentrations of human IL-18BP.

(C) Mouse splenocytes were incubated (24 h) with LPS (10 μ g/ml) together with increasing concentrations of human IL-18BP.

15 (D) Mouse splenocytes were incubated (24 h) with Con A (1 μ g/ml), together with increasing concentrations of human IL-18BP.

(E) Human KG-1 cells were stimulated with TNF- α (20 ng/ml) and huIL-18 (25 ng/ml), added either alone, or after pre-mixing (1 h, 37°C) with urinary IL-18BP.

20 **Figure 4** shows the sequence of human IL-18BP_a cDNA and protein. The signal peptide is underlined.

Figure 5 shows the sequence of human IL-18BP_b cDNA and protein. The signal peptide is underlined.

25 **Figure 6** shows the sequence of human IL-18BP_c cDNA and protein. The signal peptide is underlined.

Figure 7 shows the sequence of human IL-18BP_d cDNA and protein. The signal peptide is underlined.

30

Figure 8 shows the sequence of human IL-18BP gene. The sequence of a human genomic clone (7.1 kb) was determined and compared with that of the various cDNA clones isolated from 3 cDNA libraries. the common translation start codon is nucleotides 683-685. The NuMA1 gene is located on the negative strand, from nucleotide 3578 to the end.

5

Figure 9 shows the effect of recombinant IL-18BP on human and mouse IL-18 activity.

His₆-tagged IL-18BPa was transiently expressed in COS7 cells and purified.

(A) Human IL-18 (5 ng/ml) was pre-mixed with either His₆-tagged-IL-18BPa or 10 RPMI and added to mouse spleen cells together with LPS (1 µg/ml). IFN-γ production was measured after 24 h.

(B) Mouse IL-18 (10 ng/ml) was pre-mixed with either His₆-tagged-IL-18BPa or RPMI and added to mouse spleen cells together with LPS (1 µg/ml). IFN-γ production was measured after 24 h.

15 (C) Human IL-18 (25 ng/ml) was pre-mixed with either COS7-IL-18BPa or RPMI and added to Human PBMC in the presence of IL-12 (10 ng/ml).

(D) Human IL-18 (25 ng/ml) was pre-mixed with either COS7-IL-18BPa or RPMI and added to Human KG-1 cells in the presence of TNF-α (20 ng/ml).

20 **Detailed Description of the Invention**

The present invention relates to various IL-18BPs and viral IL-18BPs which bind to IL-18. Such IL-18BPs may be capable of modulating and/or blocking the biological activities of IL-18. The term, "IL-18BPs and viral IL-18BPs," includes the mature protein (without the signal sequence), the protein comprising signal sequences, muteins of IL-18BPs and viral 25 IL-18BPs, derivatives of IL-18BPs and viral IL-18BPs and truncated forms of IL-18BPs and viral IL-18BPs and salts thereof.

The invention further relates to replicable expression vehicles, suitable for expression of various IL-18BPs or viral IL-18BPs in host cells and host bacteria. The invention further relates to expression vectors, suitable for expression of various IL-18BPs or viral IL-18BPs 30 in humans and in other mammals.

The invention further relates to DNAs coding for various IL-18BPs, viral IL-18BPs, muteins, fused proteins, functional derivatives, active fractions and mixtures thereof. Said DNA may be a genomic DNA, a cDNA, a synthetic DNA, a PCR product or combinations thereof. These DNAs may be inserted into replicable expression vehicles for expression of various IL-18BPs and viral IL-18BPs in host cells, according to the invention. DNAs capable of hybridizing to the above DNAs under stringent conditions and encoding proteins or polypeptides which are also capable of binding IL-18 are also included in the present invention.

One such DNA encodes an IL-18BP including the amino acid sequence of SEQ ID NO:10 and provided with a stop codon at its 3' end.

The expression vectors, suitable for expression of various IL-18BPs or viral IL-18BPs in humans and in other mammals, i.e. for gene therapy, may be viral vectors or other types of vectors in which an IL-18BP gene or an IL-18BP cDNA or a DNA encoding a viral IL-18BP was inserted in a way that enables efficient expression of an IL-18BP or a viral IL-18BP in humans and other mammals. DNA molecules hybridizing to the above DNAs under stringent conditions and encoding proteins or polypeptides which are capable of binding IL-18, are also included in the present invention.

Isolation of IL-18BP may be carried out in accordance with the invention, e.g. by passing a human fluid, such as urine or serum, through a chromatographic column to which IL-18 is coupled, and thereafter, eluting the bound IL-18BP.

The various IL-18BPs and viral IL-18BPs can also be prepared by recombinant means, i.e. by expressing IL-18BP in a suitable host, after operatively linking promoters, expression enhancers, regulatory sequences, etc., suitable for the particular host employed which e.g. allow expression in the correct orientation.

The various IL-18BPs and viral IL-18BPs and vectors for expressing IL-18Bp in humans and other mammals may be employed in the treatment and alleviation of conditions in which IL-18 is involved or caused by an excess of exogenously administered or endogenously produced IL-18. Such conditions are, e.g., autoimmune diseases, type I diabetes, rheumatoid arthritis, graft rejections, inflammatory bowel disease, sepsis, multiple sclerosis, ischemic heart diseases (including heart attacks), ischemic brain injury, chronic hepatitis, psoriasis, chronic pancreatitis, acute pancreatitis and the like.

According to the present invention, IL-18BP was isolated from normal human urine by one chromatographic step. A preparation of crude human urinary proteins concentrated from 500l of normal human urine was loaded on a column consisting of human IL-18 bound to agarose. The column was washed and bound proteins were eluted at low pH. Eluted fractions were neutralized and aliquots were analyzed by SDS-PAGE (10% acrylamide) under non-reducing conditions and silver staining. A protein band of ~40 kD was specifically obtained in the eluted fractions (Fig. 1).

The ~40 kD protein obtained in the first step was identified as an IL-18 binding protein by its ability to specifically cross-link with ^{125}I -IL-18 (Fig. 2). The ~40 kD protein 10 was further characterized by N-terminal protein sequence analysis. Aliquots from the eluted protein were subjected to SDS-PAGE, electroblotted to a PVDF membrane and subjected to protein microsequence analysis. Similarly, aliquots from the eluted protein were subjected to direct protein microsequence analysis. In both cases, two polypeptide sequences were obtained. A major sequence and a minor sequence, the latter corresponding to a fragment of 15 human defensin (accession number p11398), starting at amino acid 65. Subtraction of the known defensin sequence provided the following sequence:

T-P-V-S-Q-Q-x-x-A-A-A

1 . . . 5 . . . 10 . .

wherein x represents a yet undetermined amino acid.

In order to obtain a longer and more accurate sequence and in order to identify potential cysteine residues, an aliquot of the eluted fraction was reduced with DTT under denaturing conditions, reacted with 4-vinyl pyridine, desalted by a micro-ultrafiltration device (Ultrafree, cutoff 10,000 Da, Millipore) and subjected to protein microsequence analysis. After sequencing cycle No. 1 the residual protein was reacted with o-phtalaldehyde 20 to block all N-terminal polypeptides other than Pro and sequencing was then resumed. In this way the following single protein sequence was obtained:

TPVSQXXXAA XASVRSTKDP CPSQPPVFPA AKQCPALEVT

1 10 20 30 40

30 (T=Thr; P=Pro; V=Val; S=Ser; Q=Gln; X=Unknown; A=Ala; R=Arg; K=Lys; D=Asp; C=Cys; F=Phe; L=Leu; E=Glu)

The resulting sequence is significantly different from that of any other known protein, as determined by searching protein databases. However, searching the database of The Institute of Genomic Research (TIGR) (<HTTP://www.ncbi.nlm.nih.gov>) by the tblastn search program provided a cDNA file, denoted THC123801, whose open reading frame (218 codons), when translated, contains a sequence highly homologous to that of the N-terminal sequence of IL-18BP. The homology is hereby shown:

10

(The upper sequence (1-40) is that of the IL-18BP isolated according to the invention; the lower sequence (51-100) is deduced by translation of the cDNA of TIGR file THC123801).

The cDNA sequence identified as THC123801 is, however, only an EST (expressed sequence tag), i.e. a randomly selected cDNA clone. It has never been analyzed whether this EST contains an open reading frame, whether a protein is expressed from the gene corresponding to the EST or from the EST itself, nor has any function of a protein encoded by THC123801 ever been identified. No information was available at all that THC123801 contains an open reading frame coding for an IL-18BP.

The affinity-purified urinary IL-18BP retained the ability to bind its labeled ligand (125I-IL-18), and following covalent cross-linking, a complex of molecular weight 58 kD was formed. The molecular weight of this complex corresponded to a 1:1 ratio of the ~40 kD IL-18BP and the 19 kD IL-18 (Fig. 2).

The affinity-purified urinary IL-18BP blocked the biological activity of human as well as mouse IL-18. Thus when IL-18BP was added to either human or mouse IL-18 it blocked the ability of IL-18 to induce the production of interferon- γ when added together with lipopolysaccharide (LPS) to cultures of mouse spleen cells (Fig. 3).

For the purpose of the present description the expression "biological activity of IL-18" refers inter alia to at least one of the following biological properties:

30 (i) induction of IFN- γ , primarily as a co-stimulant with mitogens, IL-1, IL-12,
 TNF- α , LPS in various cell types, such as mononuclear cells, murine

splenocytes, human peripheral blood mononuclear cells, the human KG-1 cell line and T-cells,

- (ii) enhancement of T-cell proliferation,
- 5 (iii) enhancement of Th-1 cytokine production *in vitro*, primarily as a co-stimulant,
- (iv) synergism with IL-12 in terms of enhanced IFN- γ production, co-stimulatory action for production of IFN- γ and other T-helper cell-1 cytokines,
- (v) co-stimulatory action for FAS ligand-mediated cytotoxicity of murine natural killer cell clones,
- 10 (vi) induction of the activation of NF- κ B in human KG-1 cells, probably by inducing the formation of the p50 NF- κ B homodimer and the p65/p50 NF- κ B heterodimer,
- (vii) induction of IL-8.

15 As used herein, the expression "binding to IL-18" means the capability of IL-18BP to bind IL-18, e.g. as evidenced by its binding to labeled IL-18 when affinity purified as in Example 2 herein.

As used herein, the expression "modulating the activity of IL-18" means the capability of IL-18BP to modulate any IL-18 activity other than blocking, e.g. partial inhibition, enhancement, or the like.

20 As used herein, the expression "blocking the activity of IL-18" refers to the activity of IL-18BP to block at least one of the above exemplified biological activities of IL-18. The IL-18 blocking activity of IL-18BP is exemplified by the ability of IL-18BP to block the IL-18 associated IFN- γ expression in murine splenocytes. As it will be shown below in more detail, the modulating or blocking activity of IL-18BP is in part due to the fact that IL-18BP inhibits the activation of NF- κ B by IL-18. Furthermore, IL-18BP blocks at least one of the following activities of IL-18, namely induction of IFN- γ in human and mouse cells, induction of IL-8 and activation of NF- κ B.

30 A DNA probe for screening cDNA libraries was prepared by reverse-transcription PCR with specific sense and antisense primers and RNA from the human Jurkat T cells with primers from the TIGR sequence. The resulting PCR product was confirmed by DNA

sequence analysis. This PCR product was labeled with ^{32}P and used as a probe for screening of four human cDNA libraries, derived from peripheral blood monocytes, from the Jurkat T-cell line, from PBMC and from human spleen. The various independent cDNA clones corresponded to four IL-18BP splice variants (SEQ ID NO:1, 3, 5 and 7). All splice
5 variants coded for putative soluble secreted proteins. The most abundant one (IL-18BPa) had an open reading frame of 192 codons, coding for a signal peptide herein sometimes referred to as a "leader sequence" of 28 amino acid residues followed by a mature putative IL-18BPa, whose first 40 residues matched perfectly with the N-terminal protein sequence of the urinary IL-18BP (SEQ ID NO:2). The position of the cysteine residues suggested that this
10 polypeptide belongs to the immunoglobulin (Ig) super-family. Interestingly, each of the four Gln residues within mature IL-18BPa was a potential N-glycosylation site. The three other variants of IL-18BP were less abundant than IL-18BPa. They included a shorter 1 kb IL-18BPb cDNA, coding for a signal peptide of 28 amino acid residues followed by a mature protein of 85 amino acid residues (SEQ ID NO:4). A third variant, IL-18BPC was represented
15 by a 2.3 kb cDNA, coding for a signal peptide of 28 amino acid residues followed by a mature IL-18BP of 169 amino acid residues (SEQ ID NO:6). The fourth variant, IL-18BPD, coded for a signal peptide of 28 amino acid residues followed by a mature IL-18BP of 133 amino acid residues (SEQ ID NO:8).

To further study the possible existence of additional IL-18BP splice variants, a
20 human genomic library was screened with a probe corresponding to full length IL-18BP cDNA. Five genomic clones, differing in length, were identified in this library. These clones were subjected to DNA sequence analysis with external and internal primers. Altogether, a 7.8 kb sequence was assembled from these clones (SEQ ID NO:9). No exon coding for a trans-membrane (TM) receptor was identified within the 7.8 kb sequence. All variants shared
25 a common translation start site, coded for the same signal peptide of 28 amino acid residues and soluble mature proteins of varying sizes and C-terminal sequences. The IL-18BP locus contains an additional gene, coding for the nuclear mitotic apparatus protein 1 (NUMA1), positioned at the minus strand. This finding localizes the IL-18BP gene to human chromosome 11q13 (36).

30 An homology search was done with the complete protein sequence of IL-18BPa and the GenPept database (<HTTP://www.ncbi.nlm.nih.gov>), using the Smith Watermann

algorithm. It was found that homologues of IL-18BP are expressed in several Poxviruses as secreted proteins of a previously unknown function. It was previously reported that viruses code for various cytokine receptors and that such virally encoded molecules serve as decoy receptors that inhibit immune responses by neutralizing their corresponding cytokine 5 (reviewed by Spriggs, MK, 1994, Curr. Opin. Immunol., 6, 526-529). Therefore the invention further relates to virally encoded homologues of IL-18BP that may also serve as blockers or modulators of the biological activity of IL-18. Examples of virus-encoded homologues of IL-18BP are provided in Table 1.

According to the present invention the virus encoded homologue of IL-18BP may be 10 expressed in a prokaryotic or eukaryotic host. As used herein, the expression "virus encoded homologue-IL-18BP" refers to a similarity of at least 50% in a sequence of at least 70 amino acid residues. More preferably, it has at least 50%, at least 60%, at least 70%, at least 80% or, most preferably, at least 90% similarity thereto in a sequence of 100 amino acid residues.

15 Table 1. Virus-encoded proteins, showing high homology to human IL-18BP

GenPept sequence	Virus type
MCU60315_54	U60315 Molluscum contagiosum virus subtype 1
MCU60315_53	U60315 Molluscum contagiosum virus subtype 1
SWPHLSB_12	L22013 Swinepox virus
CV41KBPL_14	Cowpox virus
VVCGAA_5	Variola virus
U01161_3 174	Ectromelia virus (mouse Poxvirus)
VVU18340_6	Variola virus
VVU18338_7	Variola virus
VVU18337_7	Variola virus
VARCG_7 173	Variola major virus
MCU60315_51	Molluscum contagiosum virus
HNABV_1	New Hepatitis non-A, non-B associated virus

IL-18BP_a was expressed in monkey COS7 cells. For this purpose, the cDNA of IL-18BP_a was inserted into the mammalian expression vector pEF-BOS. A cassette coding for an (His)₆ sequence was added to the 3'-end of the IL-18BP ORFs in frame, in order to facilitate purification of the recombinant protein. COS7 cells were transiently transfected
5 with the expression vector and serum-free medium of these cells (150 ml) was concentrated and purified by metal chelate chromatography. IL-18BP_a ran as a single band upon SDS-PAGE with silver staining under reducing and non-reducing conditions and had the same apparent molecular mass as that of the urinary IL-18BP. Protein sequence analysis of this preparation revealed the same N-terminal sequence as that of the urinary IL-18BP.
10 Immunoblot analysis of IL-18BP_a with antibodies raised against the urinary IL-18BP revealed the same molecular mass band as that of the urinary protein. Furthermore, using immunoprecipitation followed by SDS-PAGE and autoradiography, IL-18BP_a was able to displace urinary ¹²⁵I-IL-18BP from binding to the antibody. Therefore, IL-18BP_a corresponds structurally to the IL-18BP isolated from urine.

15 Crude and purified IL-18BP_a were tested for their ability to inhibit the biological activity of IL-18. IL-18BP_a inhibited the activity of human and mouse IL-18 in murine splenocytes, PBMC and the human KG-1 cell line (Fig. 9). These results confirm the identity of IL-18BP_a cDNA as the one coding for a biologically active IL-18BP.

20 The invention further relates to muteins and fragments of IL-18BPs and viral IL-18BPs and to fused proteins consisting of wild type IL-18BPs and viral IL-18BPs or their muteins or their fragments, fused to another polypeptide or protein and being capable of binding IL-18 or its homologues.

25 As used herein the term "muteins" refers to analogs of an IL-18BP, or analogs of a viral IL-18BP, in which one or more of the amino acid residues of a natural IL-18BP or viral IL-18BP are replaced by different amino acid residues, or are deleted, or one or more amino acid residues are added to the natural sequence of an IL-18BP, or a viral IL-18BP, without changing considerably the capability of the resulting products as compared with the wild type IL-18BP or viral IL-18BP to bind to IL-18. These muteins are prepared by known synthesis and/or by site-directed mutagenesis techniques, or any other known technique suitable
30 therefor.

Any such mutein preferably has a sequence of amino acids sufficiently duplicative of that of an IL-18BP, or sufficiently duplicative of a viral IL-18BP, such as to have substantially similar activity to IL-18BP. One activity of IL-18BP is its capability of binding IL-18. As long as the mutein has substantial binding activity to IL-18, it can be used in the purification of IL-18, such as by means of affinity chromatography, and thus can be considered to have substantially similar activity to IL-18BP. Thus, it can be determined whether any given mutein has substantially the same activity as IL-18BP by means of routine experimentation comprising subjecting such a mutein, e.g., to a simple sandwich competition assay to determine whether or not it binds to an appropriately labeled IL-18, such as 10 radioimmunoassay or ELISA assay.

In a preferred embodiment, any such mutein has at least 40% identity or homology with the sequence of either an IL-18BP or a virally-encoded IL-18BP homologue. More preferably, it has at least 50%, at least 60%, at least 70%, at least 80% or, most preferably, at least 90% identity or homology thereto.

Muteins of IL-18BP polypeptides or muteins of viral IL-18BPs, which can be used in accordance with the present invention, or nucleic acid coding therefor, include a finite set of substantially corresponding sequences as substitution peptides or polynucleotides which can be routinely obtained by one of ordinary skill in the art, without undue experimentation, based on the teachings and guidance presented herein. For a detailed description of protein chemistry and structure, see Schulz, G.E. et al., *Principles of Protein Structure*, Springer-Verlag, New York, 1978; and Creighton, T.E., *Proteins: Structure and Molecular Properties*, W.H. Freeman & Co., San Francisco, 1983, which are hereby incorporated by reference. For a presentation of nucleotide sequence substitutions, such as codon preferences, see Ausubel et al, *supra*, at §§ A.1.1-A.1.24, and Sambrook et al, *supra*, at Appendices C 20 and D.

Preferred changes for muteins in accordance with the present invention are what are known as "conservative" substitutions. Conservative amino acid substitutions of IL-18BP polypeptides or proteins or viral IL-18BPs, may include synonymous amino acids within a group which have sufficiently similar physicochemical properties that substitution between 30 members of the group will preserve the biological function of the molecule, Grantham, Science, Vol. 185, pp. 862-864 (1974). It is clear that insertions and deletions of amino acids

may also be made in the above-defined sequences without altering their function, particularly if the insertions or deletions only involve a few amino acids, e.g., under thirty, and preferably under ten, and do not remove or displace amino acids which are critical to a functional conformation, e.g., cysteine residues, Anfinsen, "Principles That Govern The Folding of Protein Chains", Science, Vol. 181, pp. 223-230 (1973). Proteins and muteins produced by such deletions and/or insertions come within the purview of the present invention.

However, cysteine residues which are not required for biological activity may be replaced with other residues, e.g. in order to avoid the formation of undesired intramolecular or intermolecular disulfide bridges which may cause a reduction in the activity of the IL-18BPs.

Preferably, the synonymous amino acid groups are those defined in Table I. More preferably, the synonymous amino acid groups are those defined in Table II; and most preferably the synonymous amino acid groups are those defined in Table III.

15

20

25

30

TABLE I**Preferred Groups of Synonymous Amino Acids**

	Amino Acid	Synonymous Group
5	Ser	Ser, Thr, Gly, Asn
	Arg	Arg, Gln, Lys, Glu, His
	Leu	Ile, Phe, Tyr, Met, Val, Leu
	Pro	Gly, Ala, Thr, Pro
	Thr	Pro, Ser, Ala, Gly, His, Gln, Thr
10	Ala	Gly, Thr, Pro, Ala
	Val	Met, Tyr, Phe, Ile, Leu, Val
	Gly	Ala, Thr, Pro, Ser, Gly
	Ile	Met, Tyr, Phe, Val, Leu, Ile
	Phe	Trp, Met, Tyr, Ile, Val, Leu, Phe
15	Tyr	Trp, Met, Phe, Ile, Val, Leu, Tyr
	Cys	Ser, Thr, Cys
	His	Glu, Lys, Gln, Thr, Arg, His
	Gln	Glu, Lys, Asn, His, Thr, Arg, Gln
	Asn	Gln, Asp, Ser, Asn
20	Lys	Glu, Gln, His, Arg, Lys
	Asp	Glu, Asn, Asp
	Glu	Asp, Lys, Asn, Gln, His, Arg, Glu
	Met	Phe, Ile, Val, Leu, Met
	Trp	Trp

25

30

TABLE II**More Preferred Groups of Synonymous Amino Acids**

	Amino Acid	Synonymous Group
5	Ser	Ser
	Arg	His, Lys, Arg
	Leu	Leu, Ile, Phe, Met
	Pro	Ala, Pro
	Thr	Thr
10	Ala	Pro, Ala
	Val	Val, Met, Ile
	Gly	Gly
	Ile	Ile, Met, Phe, Val, Leu
	Phe	Met, Tyr, Ile, Leu, Phe
15	Tyr	Phe, Tyr
	Cys	Cys, Ser
	His	His, Gln, Arg
	Gln	Glu, Gln, His
	Asn	Asp, Asn
20	Lys	Lys, Arg
	Asp	Asp, Asn
	Glu	Glu, Gln
	Met	Met, Phe, Ile, Val, Leu
	Trp	Trp

TABLE III**Most Preferred Groups of Synonymous Amino Acids**

	Amino Acid	Synonymous Group
5	Ser	Ser
	Arg	Arg
	Leu	Leu, Ile, Met
	Pro	Pro
	Thr	Thr
10	Ala	Ala
	Val	Val
	Gly	Gly
	Ile	Ile, Met, Leu
	Phe	Phe
15	Tyr	Tyr
	Cys	Cys, Ser
	His	His
	Gln	Gln
	Asn	Asn
20	Lys	Lys
	Asp	Asp
	Glu	Glu
	Met	Met, Ile, Leu
	Trp	Met

25 Examples of production of amino acid substitutions in proteins which can be used for obtaining muteins of IL-18BP polypeptides or proteins, or muteins of viral IL-18BPs, for use in the present invention include any known method steps, such as presented in US patents RE 33,653, 4,959,314, 4,588,585 and 4,737,462, to Mark et al; 5,116,943 to Koths et al., 4,965,195 to Namen et al; 4,879,111 to Chong et al; and 5,017,691 to Lee et al; and lysine 30 substituted proteins presented in US patent No. 4,904,584 (Shaw et al).

In another preferred embodiment of the present invention, any mutein of an IL-18BP or a viral IL-18BP, has an amino acid sequence essentially corresponding to that of an IL-18BP, or to a viral IL-18BP. The term "essentially corresponding to" is intended to comprehend proteins with minor changes to the sequence of the natural protein which do not affect the basic characteristics of the natural proteins, particularly insofar as their ability to bind IL-18. The type of changes which are generally considered to fall within the "essentially corresponding to" language are those which would result from conventional mutagenesis techniques of the DNA encoding these proteins, resulting in a few minor modifications, and screening for the desired activity in the manner discussed above. In addition to binding IL-18, the muteins may also modulate and/or block IL-18 activity.

Muteins in accordance with the present invention include proteins encoded by a nucleic acid, such as DNA or RNA, which hybridizes to DNA or RNA, which encodes an IL-18BP or encodes a viral IL-18BP, in accordance with the present invention, under stringent conditions. The invention also includes such nucleic acid, which is also useful as a probe in identification and purification of the desired nucleic acid. Furthermore, such nucleic acid would be a prime candidate to determine whether it encodes a polypeptide, which retains the functional activity of an IL-18BP of the present invention. The term "stringent conditions" refers to hybridization and subsequent washing conditions, which those of ordinary skill in the art conventionally refer to as "stringent". See Ausubel et al., Current Protocols in Molecular Biology, supra, Interscience, N.Y., §§6.3 and 6.4 (1987, 1992), and Sambrook et al., supra. Without limitation, examples of stringent conditions include washing conditions 12-20°C below the calculated Tm of the hybrid under study in, e.g., 2 x SSC and 0.5% SDS for 5 minutes, 2 x SSC and 0.1% SDS for 15 minutes; 0.1 x SSC and 0.5% SDS at 37°C for 30-60 minutes and then, a 0.1 x SSC and 0.5% SDS at 68°C for 30-60 minutes. Those of ordinary skill in this art understand that stringency conditions also depend on the length of the DNA sequences, oligonucleotide probes (such as 10-40 bases) or mixed oligonucleotide probes. If mixed probes are used, it is preferable to use tetramethyl ammonium chloride (TMAC) instead of SSC. See Ausubel, supra.

The invention further includes nucleic acids which code for IL-18BP according to the present invention, but which differ in codon sequence due to the degeneracy of the genetic

code. Such a DNA which possibly does not hybridize under stringent conditions to the DNA sequences shown in Figures 4 to 7, but is nevertheless capable of encoding an IL-18BP according to the present invention is also included by the invention.

The term "fused protein" refers to a polypeptide comprising an IL-18BP, or a viral 5 IL-18BP, or a mutein thereof, fused with another protein, which, *e.g.*, has an extended residence time in body fluids. An IL-18BP or a viral IL-18BP, may thus be fused to another protein, polypeptide or the like, *e.g.*, an immunoglobulin or a fragment thereof. It may also be fused to polyethylene glycol (PEG) in order to prolong residence time.

The term "salts" herein refers to both salts of carboxyl groups and to acid addition 10 salts of amino groups of an IL-18BP, a viral IL-18BP, muteins, or fused proteins thereof. Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts with organic bases as those formed, for example, with amines, such as triethanolamine, arginine or lysine, piperidine, procaine and the like. Acid addition salts include, for example, 15 salts with mineral acids such as, for example, hydrochloric acid or sulfuric acid, and salts with organic acids such as, for example, acetic acid or oxalic acid. Of course, any such salts must have substantially similar activity to IL-18BP.

"Functional derivatives" as used herein cover derivatives of IL-18BPs or a viral 20 IL-18BP, and their muteins and fused proteins, which may be prepared *e.g.* from the functional groups which occur as side chains on the residues or the N- or C-terminal groups, by means known in the art, and are included in the invention as long as they remain pharmaceutically acceptable, *i.e.* they do not destroy the activity of the protein which is substantially similar to the activity of IL-18BP, or viral IL-18BPs, and do not confer toxic properties on compositions containing it. These derivatives may, for example, include 25 polyethylene glycol side-chains, which may mask antigenic sites and extend the residence of an IL-18BP or a viral IL-18BP in body fluids. Other derivatives include aliphatic esters of the carboxyl groups, amides of the carboxyl groups by reaction with ammonia or with primary or secondary amines, N-acyl derivatives of free amino groups of the amino acid residues formed with acyl moieties (*e.g.* alkanoyl or carbocyclic aroyl groups) or O-acyl derivatives of

free hydroxyl groups (for example that of seryl or threonyl residues) formed with acyl moieties.

As "active fractions" of an IL-18BP, or a viral IL-18BP, muteins and fused proteins, the present invention covers any fragment or precursors of the polypeptide chain of the protein molecule alone or together with associated molecules or residues linked thereto, e.g., sugar or phosphate residues, or aggregates of the protein molecule or the sugar residues by themselves, provided said fraction substantially retains the capability of binding IL-18.

The term "circularly permuted derivatives" as used herein refers to a linear molecule in which the termini have been joined together, either directly or through a linker, to produce a circular molecule, and then the circular molecule is opened at another location to produce a new linear molecule with termini different from the termini in the original molecule. Circular permutations include those molecules whose structure is equivalent to a molecule that has been circularized and then opened. Thus, a circularly permuted molecule may be synthesized *de novo* as a linear molecule and never go through a circularization and opening step. The preparation of circularly permuted derivatives is described in WO95/27732.

Various recombinant cells such as prokaryotic cells, e.g., *E. coli*, or other eukaryotic cells, such as yeast or insect cells can produce IL-18BPs or viral IL-18BPs. Methods for constructing appropriate vectors, carrying DNA that codes for an IL-18BP and suitable for transforming (e.g., *E. coli*, mammalian cells and yeast cells), or infecting insect cells in order to produce a recombinant IL-18BP or a viral IL-18BP are well known in the art. See, for example, Ausubel et al., eds. "Current Protocols in Molecular Biology" Current Protocols, 1993; and Sambrook et al., eds. "Molecular Cloning: A Laboratory Manual", 2nd ed., Cold Spring Harbor Press, 1989.

For the purposes of expression of IL-18BP proteins, or viral IL-18BPs, DNA encoding an IL-18BP or a viral IL-18BP, their fragments, muteins or fused proteins, and the operably linked transcriptional and translational regulatory signals, are inserted into vectors which are capable of integrating the desired gene sequences into the host cell chromosome. In order to be able to select the cells which have stably integrated the introduced DNA into their chromosomes, one or more markers which allow for selection of host cells which contain the expression vector is used. The marker may provide for prototrophy to an auxotrophic host, biocide resistance, e.g., antibiotics, or resistance to heavy metals, such as

copper, or the like. The selectable marker gene can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by cotransfection. Additional elements may also be needed for optimal synthesis of single chain binding protein mRNA. These elements may include splice signals, as well as transcription promoters, enhancers, and 5 termination signals.

Said DNA molecule to be introduced into the cells of choice will preferably be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Preferred prokaryotic plasmids are derivatives of pBr322. Preferred eukaryotic vectors include BPV, vaccinia, SV40, 2-micron circle, etc., or their derivatives. Such plasmids and 10 vectors are well known in the art (2-5, 22). Once the vector or DNA sequence containing the construct(s) has been prepared for expression, the expression vector may be introduced into an appropriate host cell by any of a variety of suitable means, such as transformation, transfection, lipofection, conjugation, protoplast fusion, electroporation, calcium phosphate precipitation, direct microinjection, etc.

15 Host cells to be used in this invention may be either prokaryotic or eukaryotic. Preferred prokaryotic hosts include bacteria such as E. coli, Bacillus, Streptomyces, Pseudomonas, Salmonella, Serratia, etc. The most preferred prokaryotic host is E. coli. Bacterial hosts of particular interest include E. coli K12 strain 294 (ATCC 31446), E. coli X1776 (ATCC 31537), E. coli W3110 (F⁻, lambda⁻, phototropic (ATCC 27325). Under such 20 conditions, the protein will not be glycosylated. The prokaryotic host must be compatible with the replicon and control sequences in the expression plasmid.

However, since natural IL-18BPs are glycosylated proteins, eukaryotic hosts are preferred over prokaryotic hosts. Preferred eukaryotic hosts are mammalian cells, e.g., human, monkey, mouse and Chinese hamster ovary (CHO) cells, because they provide 25 post-translational modifications to protein molecules including correct folding, correct disulfide bond formation, as well as glycosylation at correct sites. Also yeast cells and insect cells can carry out post-translational peptide modifications including high mannose glycosylation.

A number of recombinant DNA strategies exist which utilize strong promoter 30 sequences and high copy number of plasmids, which can be utilized for production of the desired proteins in yeast and in insect cells. Yeast and insect cells recognize leader sequences

on cloned mammalian gene products and secrete mature IL-18BP. After the introduction of the vector, the host cells are grown in a selective medium, which selects for the growth of vector-containing cells. Expression of the cloned gene sequence(s) results in the production of an IL-18BP, a viral IL-18BP, fusion proteins, or muteins or fragments thereof. The 5 above-mentioned cloning, clone isolation, identification, characterization and sequencing procedures are described in more detail hereinafter in the Examples.

The expressed proteins are then isolated and purified by any conventional procedure involving extraction, precipitation, chromatography, electrophoresis, or the like, or by 10 affinity chromatography, using, e.g., an anti-IL-18BP monoclonal antibodies immobilized on a gel matrix contained-within a column. Crude preparations containing said recombinant IL-18BP are passed through the column whereby IL-18BP will be bound to the column by the specific antibody, while the impurities will pass through. After washing, the protein is eluted from the gel under conditions usually employed for this purpose, *i.e.* at a high or a low 15 pH, *e.g.* pH 11 or pH 2.

The invention further relates to vectors useful for expression of an IL-18BP or a viral IL-18BP or their derivatives in mammals and more specifically in humans. Vectors for short and long-term expression of genes in mammals are well known in the literature. Studies have shown that gene delivery to *e.g.*, skeletal muscle, vascular smooth muscle and liver result in 20 systemic levels of therapeutic proteins. Skeletal muscle is a useful target because of its large mass, vascularity and accessibility. However, other targets and particularly bone marrow precursors of immune cells have been used successfully. Currently available vectors for expression of proteins in *e.g.*, muscle include plasmid DNA, liposomes, protein-DNA conjugates and vectors based on adenovirus, adeno-associated virus and herpes virus. Of 25 these, vectors based on adeno-associated virus (AAV) have been most successful with respect to duration and levels of gene expression and with respect to safety considerations (Kessler, P.D. 1996, Proc. Natl. Acad. Sci. USA 93, 14082-14087).

Procedures for construction of an AAV-based vector have been described in detail (Snyder et al, 1996, Current Protocols in Human Genetics, Chapters 12.1.1-12.1.17, John 30 Wiley & Sons) and are incorporated into this patent. Briefly plasmid psub201, containing the wild-type AAV genome is cut with the restriction enzyme Xba I and ligated with a construct

consisting of an efficient eukaryotic promoter, e.g., the cytomegalovirus promoter, a Kozak consensus sequence, a DNA sequence coding for an IL-18BP or a viral IL-18BP, or their muteins or fusion proteins or fragments thereof, a suitable 3' untranslated region and a polyadenylation signal, e.g., the polyadenylation signal of simian virus 40. The resulting recombinant plasmid is cotransfected with an helper AAV plasmid e.g., pAAV/Ad into mammalian cells e.g., human T293 cells. The cultures are then infected with adenovirus as a helper virus and culture supernatants are collected after 48-60 hours. The supernatants are fractionated by ammonium sulfate precipitation, purified on a CsCl density gradient, dialyzed and then heated at 56°C to destroy any adenovirus, whereas the resulting recombinant AAV, capable of expressing IL-18BP or a viral IL-18BP, or their muteins or fusion proteins remains stable at this step.

So far, the physiological role of the soluble cytokine receptors has not been established. The soluble receptors bind their specific ligands and in most cases inhibit their biological activity, as was shown, e.g., in the TNF system (11, 12). In very few cases, e.g., IL-6, the soluble receptor enhances the biological activity. The recombinant soluble TNF receptor, also known as TBP (TNF binding protein) was found to prevent septic shock in animal models, while soluble forms of IL-1 receptor were found to have profound inhibitory effects on the development of in vivo alloreactivity in mouse allograft recipients.

Similarly, the IL-18BPs and viral IL-18BPs of the present invention may find use as modulators of IL-18 activity, e.g. in type I diabetes, in sepsis, in autoimmune diseases, in graft rejections, rheumatoid arthritis, inflammatory bowel disease, sepsis, multiple sclerosis, ischemic heart disease including acute heart attacks, ischemic brain injury, chronic hepatitis, psoriasis, chronic hepatitis and acute hepatitis. They may thus be used, e.g. in any disease in which endogenous production or exogenous administration of IL-18 induces the disease or aggravates the situation of the patient.

The present invention further relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an IL-18BP or a viral IL-18BP of the invention or their active muteins, fused proteins and their salts, functional derivatives or active fractions thereof.

The present invention further relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and e.g., a viral vector such as any one of said

AAV-based viral vectors or another vector expressing an IL-18BP or viral IL-18BP or their muteins, fragments or fusion proteins thereof and suitable for administration to humans and other mammals for the purpose of attaining expression in vivo of IL-18BP or a viral IL-18BP or their muteins or fragments or fusion protein of the invention, i.e. for use in gene therapy.

5 The pharmaceutical compositions of the invention are prepared for administration by mixing an IL-18BP or a viral IL-18BP, or their derivatives, or vectors for expressing same with physiologically acceptable carriers, and/or stabilizers and/or excipients, and prepared in dosage form, e.g., by lyophilization in dosage vials. The method of administration can be via any of the accepted modes of administration for similar agents and will depend on the
10 condition to be treated, e.g., intravenously, intramuscularly, subcutaneously, by local injection or topical application, or continuously by infusion, etc. The amount of active compound to be administered will depend on the route of administration, the disease to be treated and the condition of the patient. Local injection, for instance, will require a lower amount of the protein on a body weight basis than will intravenous infusion.

15 Accordingly, IL-18BPs, or viral IL-18BPs, or vectors expressing same in vivo are indicated for the treatment of autoimmune diseases, Type I diabetes, rheumatoid arthritis, graft rejections, inflammatory bowel disease, sepsis, multiple sclerosis, ischemic heart disease including acute heart attacks, ischemic brain injury, chronic hepatitis, psoriasis, chronic pancreatitis and acute pancreatitis and similar diseases, in which there is an aberrant
20 expression of IL-18, leading to an excess of IL-18 or in cases of complications due to exogenously administered IL-18.

The invention also includes antibodies against an IL-18BP or a viral IL-18BP, as well as against their muteins, fused proteins, salts, functional derivatives and active fractions. The term "antibody" is meant to include polyclonal antibodies, monoclonal antibodies (MAbs),
25 chimeric antibodies, anti-idiotypic (anti-Id) antibodies to antibodies that can be labeled in soluble or bound form, and humanized antibodies as well as fragments thereof provided by any known technique, such as, but not limited to enzymatic cleavage, peptide synthesis or recombinant techniques.

Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen. A monoclonal antibody contains a substantially homogeneous population of antibodies specific to antigens, which population contains substantially similar epitope binding sites. MAbs may be obtained by methods known to those skilled in the art. See, for example Kohler and Milstein, Nature 256:495-497 (1975); US Patent No. 4,376,110; Ausubel et al, eds., supra, Harlow and Lane, ANTIBODIES: A LABORATORY MANUAL, Cold Spring Harbor Laboratory (1988); and Colligan et al., eds., Current Protocols in Immunology, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1992, 1993), the contents of which references are incorporated entirely herein by reference. Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, GILD and any subclass thereof. A hybridoma producing a MAb of the present invention may be cultivated *in vitro*, *in situ* or *in vivo*. Production of high titers of MAbs *in vivo* or *in situ* makes this the presently preferred method of production.

Chimeric antibodies are molecules, different portions of which are derived from different animal species, such as those having the variable region derived from a murine MAb and a human immunoglobulin constant region. Chimeric antibodies are primarily used to reduce immunogenicity in application and to increase yields in production, for example, where murine MAbs have higher yields from hybridomas but higher immunogenicity in humans, such that human/murine chimeric MAbs are used. Chimeric antibodies and methods for their production are known in the art (Cabilly et al, Proc. Natl. Acad. Sci. USA 81:3273-3277 (1984); Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984); Boulianne et al., Nature 312:643-646 (1984); Cabilly et al., European Patent Application 125023 (published November 14, 1984); Neuberger et al., Nature 314:268-270 (1985); Taniguchi et al., European Patent Application 171496 (published February 19, 1985); Morrison et al., European Patent Application 173494 (published March 5, 1986); Neuberger et al., PCT Application WO 8601533, (published March 13, 1986); Kudo et al., European Patent Application 184187 (published June 11, 1986); Morrison et al., European Patent Application 173494 (published March 5, 1986); Sahagan et al., J. Immunol. 137:1066-1074 (1986); Robinson et al., International Patent Publication, WO 9702671 (published 7 May 1987); Liu et al., Proc. Natl. Acad. Sci. USA 84:3439-3443 (1987); Sun et al., Proc. Natl.

Acad. Sci. USA 84:214-218 (1987); Better et al., Science 240:1041- 1043 (1988); and Harlow and Lane, ANTIBODIES: A LABORATORY MANUAL, supra. These references are entirely incorporated herein by reference.

An anti-idiotypic (anti-Id) antibody is an antibody, which recognizes unique determinants generally, associated with the antigen-binding site of an antibody. An Id antibody can be prepared by immunizing an animal of the same species and genetic type (e.g., mouse strain) as the source of the MAb with the MAb to which an anti-Id is being prepared. The immunized animal will recognize and respond to the idiotypic determinants of the immunizing antibody by producing an antibody to these idiotypic determinants (the anti-Id antibody). See, for example, US patent No. 4,699,880, which is herein entirely incorporated by reference.

The anti-Id antibody may also be used as an "immunogen" to induce an immune response in yet another animal, producing a so-called anti-anti-Id antibody. The anti-anti-Id may be epitopically identical to the original MAb, which induced the anti-Id. Thus, by using antibodies to the idiotypic determinants of a MAb, it is possible to identify other clones expressing antibodies of identical specificity.

Accordingly, MAbs generated against IL-18BP and related proteins of the present invention may be used to induce anti-Id antibodies in suitable animals, such as BALB/c mice. Spleen cells from such immunized mice are used to produce anti-Id hybridomas secreting anti-Id Mabs. Further, the anti-Id Mabs can be coupled to a carrier such as keyhole limpet hemocyanin (KLH) and used to immunize additional BALB/c mice. Sera from these mice will contain anti-anti-Id antibodies that have the binding properties of the original MAb specific for an IL-18BP epitope or epitopes of a viral IL-18BP.

The anti-Id MAbs thus have their own idiotypic epitopes, or "idiotopes" structurally similar to the epitope being evaluated, such as an IL-18BP or a viral IL-18BP.

The term "humanized antibody" is meant to include e.g. antibodies which were obtained by manipulating mouse antibodies through genetic engineering methods so as to be more compatible with the human body. Such humanized antibodies have reduced

immunogenicity and improved pharmacokinetics in humans. They may be prepared by techniques known in the art, such as described, e.g. for humanized anti-TNF antibodies in Molecular Immunology, Vol. 30, No. 16, pp. 1443-1453, 1993.

The term "antibody" is also meant to include both intact molecules as well as fragments thereof, such as, for example, Fab and F(ab')₂, which are capable of binding antigen. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody (Wahl et al., J. Nucl. Med. 24:316-325 (1983)). It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies useful in the present invention may be used for the detection and quantitation of an IL-18BP or a viral IL-18BP, according to the methods disclosed herein for intact antibody molecules. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments).

An antibody is said to be "capable of binding" a molecule if it is capable of specifically reacting with the molecule to thereby bind the molecule to the antibody. The term "epitope" is meant to refer to that portion of any molecule capable of being bound by an antibody which can also be recognized by that antibody. Epitopes or "antigenic determinants" usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and have specific three dimensional structural characteristics as well as specific charge characteristics.

An "antigen" is a molecule or a portion of a molecule capable of being bound by an antibody which is additionally capable of inducing an animal to produce antibody capable of binding to an epitope of that antigen. An antigen may have one or more than one epitope. The specific reaction referred to above is meant to indicate that the antigen will react, in a highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which may be evoked by other antigens.

The antibodies, including fragments of antibodies, useful in the present invention may be used to detect quantitatively or qualitatively an IL-18BP or a viral IL-18BP, or

related proteins in a sample or to detect presence of cells, which express such proteins of the present invention. This can be accomplished by immunofluorescence techniques employing a fluorescently labeled antibody (see below) coupled with light microscopic, flow cytometric, or fluorometric detection.

5 The antibodies (or fragments thereof) useful in the present invention may be employed histologically, as in immunofluorescence or immunoelectron microscopy, for *in situ* detection of an IL-18BP or a viral IL-18BP, and related proteins of the present invention. *In situ* detection may be accomplished by removing a histological specimen from a patient, and providing the a labeled antibody of the present invention to such a specimen. The
10 antibody (or fragment) is preferably provided by applying or by overlaying the labeled antibody (or fragment) to a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of an IL-18BP or a viral IL-18BP, or related proteins but also its distribution on the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of wide variety of histological methods (such as
15 staining procedures) can be modified in order to achieve such *in situ* detection.

Such assays for an IL-18BP or a viral IL-18BP, or related proteins of the present invention typically comprises incubating a biological sample, such as a biological fluid, a tissue extract, freshly harvested cells such as lymphocytes or leukocytes, or cells which have been incubated in tissue culture, in the presence of a detectably labeled antibody capable of
20 identifying IL-18BP or related proteins, and detecting the antibody by any of a number of techniques well-known in the art.

The biological sample may be treated with a solid phase support or carrier such as nitrocellulose, or other solid support or carrier which is capable of immobilizing cells, cell particles or soluble proteins. The support or carrier may then be washed with suitable buffers
25 followed by treatment with a detectably labeled antibody in accordance with the present invention. The solid phase support or carrier may then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on said solid support or carrier may then be detected by conventional means.

By "solid phase support", "solid phase carrier", "solid support", "solid carrier", "support" or "carrier" is intended any support or carrier capable of binding antigen or antibodies. Well-known supports or carriers, include glass, polystyrene, polypropylene, polyethylene, dextran, nylon amylases, natural and modified celluloses, polyacrylamides, 5 gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support or carrier configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. 10 Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports or carriers include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

15 The binding activity of a given lot of antibody in accordance with the present invention may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

Other such steps as washing, stirring, shaking, filtering and the like may be added to the assays as is customary or necessary for the particular situation.

20 One of the ways in which an antibody in accordance with the present invention can be detectably labeled is by linking the same to an enzyme and use in an enzyme immunoassay (EIA). This enzyme, in turn, when later exposed to an appropriate substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or by visual means. Enzymes 25 which can be used detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha- glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6- phosphate dehydrogenase,

glucoamylase and acetylcholinesterase. The detection can be accomplished by colorimetric methods, which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

5 Detection may be accomplished using any of a variety of other immunoassays. For example, by radioactivity labeling the antibodies or antibody fragments, it is possible to detect an IL-18BP or a viral IL-18BP, through the use of a radioimmunoassay (RIA). A good description of RIA maybe found in Laboratory Techniques and Biochemistry in Molecular Biology, by Work, T.S. et al., North Holland Publishing Company, NY (1978) with
10 particular reference to the chapter entitled "An Introduction to Radioimmuno Assay and Related Techniques" by Chard, T., incorporated by reference herein. The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.

15 It is also possible to label an antibody in accordance with the present invention with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wavelength, its presence can be then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

20 The antibody can also be detectably labeled using fluorescence emitting metals such as ¹⁵²Eu, or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriamine pentaacetic acid (ETPA).

25 The antibody can also be detectably labeled by coupling it to biotin. Biotinylated antibody can then be detected by avidin or streptavidin coupled to a fluorescent compound or to an enzyme such as peroxidase or to a radioactive isotope and the like.

25 The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.

Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

An antibody molecule of the present invention may be adapted for utilization in a immunometric assay, also known as a "two-site" or "sandwich" assay. In a typical immunometric assay, a quantity of unlabeled antibody (or fragment of antibody) is bound to a solid support or carrier and a quantity of detectably labeled soluble antibody is added to permit detection and/or quantitation of the ternary complex formed between solid-phase antibody, antigen, and labeled antibody.

Typical, and preferred, immunometric assays include "forward" assays in which the antibody bound to the solid phase is first contacted with the sample being tested to extract the antigen from the sample by formation of a binary solid phase antibody-antigen complex. After a suitable incubation period, the solid support or carrier is washed to remove the residue of the fluid sample, including unreacted antigen, if any, and then contacted with the solution containing an unknown quantity of labeled antibody (which functions as a "reporter molecule"). After a second incubation period to permit the labeled antibody to complex with the antigen bound to the solid support or carrier through the unlabeled antibody, the solid support or carrier is washed a second time to remove the unreacted labeled antibody.

In another type of "sandwich" assay, which may also be useful with the antigens of the present invention, the so-called "simultaneous" and "reverse" assays are used. A "simultaneous" assay involves a single incubation step as the antibody bound to the solid support or carrier and labeled antibody are both added to the sample being tested at the same time. After the incubation is completed, the solid support or carrier is washed to remove the residue of fluid sample and uncomplexed labeled antibody. The presence of labeled antibody

associated with the solid support or carrier is then determined as it would be in a conventional "forward" sandwich assay.

In the "reverse" assay, stepwise addition first of a solution of labeled antibody to the fluid sample followed by the addition of unlabeled antibody bound to a solid support or 5 carrier after a suitable incubation period is utilized. After a second incubation, the solid phase is washed in conventional fashion to free it of the residue of the sample being tested and the solution of unreacted labeled antibody. The determination of labeled antibody associated with a solid support or carrier is then determined as in the "simultaneous" and "forward" assays.

10 The present invention also provides DNA molecules encoding any of the proteins of the present invention as defined above, replicable expression vehicles comprising any such DNA molecules, host cells transformed with any such expression vehicles including prokaryotic and eukaryotic and host cells, preferably CHO cells. The invention also includes a process for the production of expression vectors coding for any of the proteins of the 15 present invention for the purpose of their expression in humans and other mammals.

The invention also includes a process for the production of any of the proteins of the present invention by culturing a transformed cell in accordance with the present invention and recovering the protein encoded by the DNA molecule and the expression vehicle within such transformed host cell.

20 In addition to the use of an IL-18BP or a viral IL-18BP, in modulating the activity of IL-18, they can, of course, also be employed for the purification of IL-18 itself. For this purpose, IL-18BP or a viral IL-18BP is coupled to an affinity column and crude IL-18 is passed through. The IL-18 can then be recovered from the column by, e.g., elution at low pH.

The invention will now be illustrated by the following non-limiting examples:

EXAMPLE 1: Isolation of an IL-18 binding protein

E. coli IL-18 (2.5 mg, Peprotech, NJ) was coupled to Affigel-10 (0.5 ml, BioRad), according to the manufacturer's instructions and packed into a column. Crude urinary proteins (1000-fold concentrated, 500 ml) were loaded onto the column at a flow rate of 0.25 ml/min. The column was washed with 250 ml 0.5M NaCl in phosphate buffered saline (PBS). Bound proteins were then eluted with 25 mM citric acid, pH 2.2 and benzamidine (1 mM), immediately neutralized by 1M Na₂CO₃. Fractions of 1 ml were collected. The fractions were analyzed by SDS-PAGE and silver staining. The IL-18 binding protein eluted in fractions 2-8 as a ~40,000 Dalton protein (Fig. 1). The ~40 kD band, corresponding to the IL-18BP exhibited a distinct yellow color upon silver staining. The various fractions were analyzed by cross-linking with ¹²⁵I-IL-18, SDS-PAGE and autoradiography as described in Example 2. An IL-18 binding protein was found in fractions 2-8, eluted from the IL-18-agarose column (Fig. 2).

EXAMPLE 2: Cross-linking of affinity-purified IL-18BP to labeled IL-18.

Samples (40 µl) of IL-18BP from the affinity purification step were incubated (70 min. at 4°C) with ¹²⁵I-IL-18 (5,000,000 cpm). Disuccinimidyl suberate (DSS), dissolved in dimethyl sulfoxide (Me₂SO, 20 mM), was then added to a final concentration of 2 mM and the mixture was left for 20 min. at 4°C. The reaction was stopped by the addition of 1M Tris-HCl pH 7.5, and 1M NaCl to a final concentration of 100 mM. A sample buffer containing Dithiothreitol (DTT, 25 mM final) was added and the mixtures were analyzed by SDS-PAGE (7.5 % acrylamide) followed by autoradiography (Fig. 2).

A specific band of molecular weight 58 kD, probably consisting of a ~40 kD protein cross-linked to the ~20 kD ¹²⁵I-IL-18, was observed in fractions eluted from the IL-18 affinity column (lanes 2 and 3) but not in the column wash (lane 1), containing all other crude urinary proteins.

EXAMPLE 3: Protein sequence analysis.

Eluted fractions from the affinity column of Example 1 were resolved by SDS-PAGE (10% acrylamide) under non-reducing conditions, electroblotted on a PVDF membrane (Pro-Blot, Applied Biosystems, USA). The membrane was stained with coomassie blue, the 5 ~40 kD band was excised and subjected to protein sequence analysis by a Procise microsequencer (Applied Biosystems, USA). The following major sequence was obtained:

T-P-V-S-Q-Q-x-x-x-A-A-A

1 . . . 5 . . . 10 . .

wherein x represents a yet undetermined amino acid.

10 In addition, a minor sequence was obtained:

A-x-Y-x-R-I-P-A-x-A-I-A

1 . . . 5 . . . 10 . .

Because of this double sequence it was not possible to obtain a longer sequence data.

15 The minor sequence was identified as a fragment of human defensin, (accession No. p11398) starting at amino acid 65 of defensin. The major sequence could not be associated with any other known protein, as determined by searching all available databases in NCBI and TIGR by the blastp and tblastn search programs.

20 In order to obtain a longer and more accurate sequence and in order to identify potential cysteine residues, another aliquot of the fraction eluted from the IL-18-agarose column was reduced with DTT in 6 M guanidine HCl, reacted with 4-vinyl pyridine, desalting by a micro-ultrafiltration device (Ultrafree, cutoff 10,000 Daltons, Millipore) and subjected to protein microsequence analysis. After cycle No. 1 of sequencing, the filter was reacted with o-phtalaldehyde to block all N-terminal polypeptides other than Pro. In this way only 25 the major sequence was obtained as follows:

TPVSQXXXAA XASVRSTKDP CPSQPPVFPA AKQCPALEVT

1 10 20 30 40

30 (T=Thr; P=Pro; V=Val; S=Ser; Q=Gln; X=Unknown; A=Ala; R=Arg; K=Lys; D=Asp; C=Cys; F=Phe; L=Leu; E=Glu)

In cycles 6,7,8 and 11 a low level of a Thr signal was obtained. Because of this low level we considered it more prudent not to assign a specific amino acid residue at said cycles.

The resulting sequence is significantly different from that of any other known protein, as determined by searching protein databases. However, searching the TIGR database by the 5 tblastn search program provided a cDNA file, denoted THC123801, whose open reading frame (218 codons), when translated contains a sequence highly homologous to that of the N-terminal sequence of IL-18BP. The homology is hereby shown:

```

1 .....TPVSQXXXAAXASVRSTKDPCPSQPPVFPAAKQCPalevt... 40
          | | | | | | | | | | | | | | | | | | | | | |
10      51 VTLLVRATVXQTTAATASVRSTKDPCPSQPPVFPAAKQCPalevtwpe 100

```

(The upper sequence (1-40) is that of the IL-18BP isolated according to the invention; the lower sequence (51-100) is deduced by translation of the cDNA of TIGR file THC123801).

The putative protein sequence, obtained by translating file THC123801, was ambiguous at residues 2 and 4 of the IL-18BP. It confirms the identity of amino acid residues 6,7 and 8 of IL-18BP as Thr and seems to do so also for residue 11.

EXAMPLE 4: The IL-18BP is a glycoprotein.

Aliquot (0.3 ml) of eluted fractions of Example 1 were further purified by size exclusion chromatography on a Superose 12 column (1X30 cm, Pharmacia, Sweden). The column was pre-equilibrated and eluted with phosphate buffered saline and sodium azide (0.02%) at a flow rate of 0.5 ml/min. and fractions of 1 min. were collected. The IL-18 binding protein eluted in fractions 20-25 as a ~40,000 Dalton protein, as determined by SDS-PAGE and silver staining. A sample containing the ~40,000 Dalton protein (fraction 23, 50 µl, ~50 ng protein) was reacted with N-glycosidase F (PNGase F, Biolab) according to the manufacturers instructions. Briefly, the aliquot was denatured by boiling in the presence of 5% SDS for 10 min., 10xG7 buffer (2.5 µl), 10% NP-40 (2.5 µl) and PNGase F (1 µl), 1 h at 37°C. The sample was analyzed by SDS-PAGE (10% acrylamide) under non-reducing conditions and compared with undigested IL-18BP from the same Superose 12 fraction. It was found that the ~40 kD band of IL-18BP disappeared in the PNGase-treated fraction.

New bands, corresponding to 30 kD (just above the PNGase band) and 20 kD were obtained. The elimination of the ~40 kD band indicates that this band is an N-glycosylated protein.

EXAMPLE 5: Blocking of the biological activity of IL-18 by IL-18BP.

The ability of the IL-18BP isolated from urine to block IL-18 activity was determined
5 by measuring the IL-18-induced production of IFN- γ in mononuclear cells. IL-18 induces IFN- γ when added together with either low concentration of LPS, IL-12, IL-2, or other stimulants. The activity of IL-18 was tested in murine splenocytes, in human peripheral blood mononuclear cells (PBMC) and in the human KG-1 cell line. Spleen cells were prepared from a healthy mouse, washed and suspended in RPMI 1640 medium supplemented
10 with 10% fetal bovine serum at 5×10^6 cells/ml. 1.0 ml cultures were stimulated with LPS (either 0.5 or 1 μ g/ml) together with recombinant human or murine IL-18 (either 0.5 or 5 ng/ml). Human IL-18 binding protein (0, 5 or 50 ng/ml) was added to the recombinant IL-18 before adding to spleen cells. After culturing for 24h, the spleen cells were subjected to three freeze (-70°C) and thaw (room temperature) cycles, the cellular debris was removed by
15 centrifugation and the supernatants were assayed for IFN- γ using the ELISA kits for mouse IFN- γ (Endogen). As shown in Fig. 3A, IL-18BP blocked the activity of huIL-18 in murine splenocytes in a dose-dependent manner. In contrast, as a control, soluble interferon- α/β receptor had no effect. The activity of recombinant murine IL-18 was similarly inhibited by the human IL-18BP, suggesting that human IL-18BP recognizes murine IL-18 (Fig. 3B).
20 Endogenous IL-18 is induced in murine splenocytes by high concentrations of LPS, leading to production of IFN- γ . Indeed, IFN- γ induction by LPS (10 μ g/ml) was also inhibited by the urinary IL-18BP (Fig. 3C). Concanavalin A (con A) activates T-cells to produce IFN- γ in the absence of IL-18 [13]. Indeed, induction of IFN- γ by Con A was not inhibited by IL-18BP even at high concentrations (Fig. 3D). This observation demonstrated that IL-18BP was a
25 specific inhibitor of IL-18 bioactivity rather than a non-specific inhibitor of IFN- γ production. IL-18BP also inhibited the activity of human IL-18 in human KG-1 cells induced by a combination of IL-18 and TNF- α (Fig. 3E).

The above data demonstrate that urinary IL-18BP inhibits human as well as murine IL-18 activity as measured by co-induction of IFN- γ in human and murine mononuclear cells.

The concentration of IL-18BP which reduced IL-18 activity by >90% was comparable to that of IL-18 itself, suggesting a high affinity interaction between these two proteins.

EXAMPLE 6: Isolation of cDNA clones coding for IL-18BP.

Total RNA from Jurkat T-cells (CRL 8163, American Type Culture Collection) was
5 reverse-transcribed with SuperScript RNase H⁻ reverse transcriptase (Gibco-BRL) and random primers (Promega, Madison WI). The resulting cDNA fragments were then amplified by PCR, using Taq DNA polymerase (Sigma) and primers corresponding to TIGR clone THC123801 nucleotides 24-44 (sense) and 500-481 (reverse). The amplification was done in 30 cycles of annealing (55°C, 2 min) and extension (70°C, 1 min). The resulting
10 PCR products were resolved by agarose (1%) gel electrophoresis, eluted and cloned into pGEM-Teasy TA cloning vector (Promega). DNA from individual clones was sequenced with T7 and SP6 primers.

The resulting 477 bp fragment was ³²P-labeled by random priming. This probe was used for screening various human cDNA and genomic libraries. Duplicate nitrocellulose
15 filters were lifted and hybridized with the probe at 60°C in a buffer consisting of 6xSSC, 10x Denhardt's solution, 0.1% SDS and 100 µg/ml Salmon sperm DNA. The filters were washed and exposed overnight at -80°C to Kodak XAR film. Double positive clones were plaque-purified. Plasmids were excised from the λpCEV9 clones and self-ligated. cDNA clones from other libraries were isolated according to the manufacturer's instructions.
20 Automated DNA sequence analysis of the isolated clones was performed with Models 373A and 377 sequencers (Applied Biosystems) using sense and antisense primers. Standard protocols were used for these cloning procedures (33).

The following libraries were screened: a human monocyte cDNA library, constructed in λpCEV9 cloning vector (15), kindly provided by T. Miki; a human Jurkat leukemic T-cell
25 cDNA library, a human peripheral blood leukocyte cDNA library and a human spleen cDNA library, all from Clontech (Palo Alto, CA). A human placenta genomic library in lambda FIX II vector was from Stratagene (La Jolla, CA).

All cDNA clones corresponded to four different IL-18BP splice variants were obtained and characterized. All splice variants coded for putative soluble secreted proteins.

The most abundant one (IL-18BPa) had an open reading frame of 192 codons, coding for a signal peptide of 28 amino acid residues followed by a mature putative IL-18BPa, whose first 40 residues (SEQ ID NO:10) matched perfectly with the N-terminal protein sequence of the urinary IL-18BP (SEQ ID NO:2). The position of the cysteine residues suggested that this 5 polypeptide belongs to the immunoglobulin (Ig) super-family. Each of the four Gln residues within mature IL-18BPa was a potential N-glycosylation site. The other three splice variants of IL-18BP were significantly less abundant.

Another 1 kb IL-18BPb cDNA coded for a mature protein of 85 amino acid residues (SEQ ID NO:4). A third variant, IL-18BPC, was represented by a 2.3 kb cDNA, coding for a 10 mature IL-18BP of 169 amino acid residues (SEQ ID NO:6). The fourth variant, IL-18BPD coded for a mature IL-18BP of 133 amino acid residues (SEQ ID NO:8). In-exon splicing occurred at two sites along the pro-mRNA. These events and an additional 5' exon in IL-18BPD gave rise to 3 different 5' UTRs in the various cDNA clones. It is therefore quite 15 possible that different IL-18BP variants may be generated in response to distinct transcription regulation signals.

No cDNA coding for a receptor with a transmembrane domain was found so far.

Example 7. Construction of a mammalian expression vector, production of recombinant IL-18BP, and evaluation of the biological activities of recombinant IL-18BP

20 The coding region of the IL-18BPa cDNA was amplified by PCR with the sense primer 5' TATATCTAGAGCCACCATGAGACACA^TGGACACCA

and the reverse primer:

5' ATATCTAGATTAATGATGATGATGATGACCC^TGCTGCTGTGGACTGC.

25 The PCR products were cut with Xba I and cloned into the Xba I site of the pEF-BOS expression vector (25), to yield pEF-BOS-IL-18BPa. The constructs were confirmed by DNA sequencing.

Batches of 6x10⁷ COS7 cells in 1.4 ml TD buffer, containing pEF-BOS-IL-18BPa plasmid DNA (10 µg) and DEAE-dextran (120 µg) were incubated for 30 min at room

temperature, as described (35). The cells were then washed with DMEM -10% FBS, plated for 4 hr in DMEM-10, washed and incubated for 3-5 days in serum-free DMEM. Culture medium was collected, concentrated 6-fold by ultrafiltration (10 kD cutoff) and the IL-18BP-His₆ was isolated on a Talon column (Clontech) with imidazole as eluant according
5 to the manufacturer's instructions.

Immunological cross-reactivity of the urinary and the COS7-expressed IL-18BP was assessed as follows: Urinary IL-18BP (5 µg) was labeled with ¹²⁵I by the chloramine T procedure. Supernatants of COS7 cells (250 µl) were mixed (1 h, room temperature final volume 500 µl) with the antibody to urinary IL-18BP, diluted 1:1000 in phosphate-buffered
10 saline (PBS), 0.05% Tween 20 and 0.5 % bovine serum albumin (Wash Buffer). ¹²⁵I-labeled urinary IL-18BP (10⁶ cpm) was then added and after 1 h protein G-sepharose (20 µl) was added. The mixture was suspended (1.5 h, 4°C), the beads were then isolated and washed wash 3x Wash Buffer and once in PBS. The beads were then eluted with a Sample buffer,
15 resolved by SDS-PAGE (10% acrylamide under reducing conditions followed by Autoradiography.

IL-18BPa ran as a single band upon SDS-PAGE with silver staining under reducing and non-reducing conditions and had the same apparent molecular mass as that of the urinary IL-18BP (data not shown). Protein sequence analysis of this preparation revealed the same N-terminal sequence as that of the urinary IL-18BP, indicating that the latter was not
20 degraded at its N-terminus.

Immunoblot analysis of IL-18BPa with antibodies raised against the urinary IL-18BP revealed the same molecular mass band as that of the urinary protein. Furthermore, using immunoprecipitation followed by SDS-PAGE and autoradiography, IL-18BPa was able to displace urinary ¹²⁵I-IL-18BP from binding to the antibody. Therefore, IL-18BPa corresponds
25 structurally to the urinary IL-18BP.

Crude and purified IL-18BPa was tested for its ability to inhibit the biological activity of IL-18. IL-18BPa inhibited in a dose dependent manner the IFN-γ inducing activity of human and mouse IL-18 in murine splenocytes, PBMC and the human KG-1 cell line (Fig. 9).

The results of the various bioassays as well as the mobility shift assay (Example 8) demonstrated that inhibition of IL-18 activity is an intrinsic property of the cloned IL-18BP and not that of any accompanying impurities in urinary IL-18BP, such as the co-eluting fragment of defensin.

5 **Example 8. Electrophoretic mobility shift assays**

The effect of the urinary and the recombinant IL-18BP on IL-18-induced activation of NF- κ B in human KG-1 cells was also studied. Human KG-1 cells (4×10^6 in 1 ml RMPI) were stimulated with either huIL-18 (10 ng/ml) or huIL-18 pre-mixed with an IL-18BP (20 min, room temperature). After 20 min at 37°C, cells were washed three times with ice-cold
10 PBS and immediately frozen in liquid nitrogen. Cell pellets were resuspended in three times the packed cell volume in buffer A (20 mM Tris pH 7.6, 0.4M NaCl, 0.2 mM EDTA, glycerol (20% by volume), 1.5 mM MgCl₂, 2 mM dithiothreitol (DDT), 0.4 mM PMSF, 1 mM Na₃VO₄, 2 μ g/ml each of leupeptin, pepstatin and aprotinin). Cell debris was removed by centrifugation (15,000xg, 15 min.), aliquots of the supernatant were frozen in liquid nitrogen
15 and stored at -80°C. Protein concentration was determined by a Bradford assay (Bio-Rad) using bovine serum albumin as standard. A double-stranded oligonucleotide corresponding to NF- κ B binding element (10 pmol, Promega) was labeled with [³²P]dCTP (300 Ci/mmol) and T4 polynucleotide kinase (New England Biolabs). Free nucleotides were removed by a spin column. Extracts (10 μ g protein) of cells treated with IL-18 or IL-18 plus IL-18BP were
20 incubated (15 min., room temperature) with the labeled probe (3×10^4 cpm) together with poly dI.dC (500 ng, Pharmacia) and denatured salmon sperm DNA (100 ng, Sigma) in 20 μ l buffer consisting of HEPES (pH 7.5, 10 mM), 60 mM KCl, 1 mM MgCl₂, 2 mM EDTA, 1 mM DTT and glycerol (5% by volume). The mixtures were then loaded onto 5% non-denaturing polyacrylamide gels. Electrophoresis was performed at 185 V in 0.5xTBE
25 (40 mM Tris HCl, 45 mM boric acid and 2.5 mM EDTA). Gels were vacuum dried and autoradiographed overnight at -80°C. IL-18 was found to induce the formation of the p50 NF- κ B homodimer and the p65/p50 NF- κ B heterodimer. Urinary as well as recombinant IL-18BP inhibited the activation of NF- κ B by IL-18, as determined by an electrophoretic mobility shift assay with KG-1 cell extracts binding a radiolabeled oligonucleotide
30 corresponding to the NF- κ B consensus sequence.

Example 9. Expression of IL-18BP in E. coli, yeast and insect cells.

IL-18BP may also be produced by other recombinant cells such as prokaryotic cells, e.g., E. coli, or other eukaryotic cells, such as yeast and insect cells. Well known methods are available for constructing appropriate vectors, carrying DNA that codes for either IL-18BP and suitable for transforming E. coli and yeast cells, or infecting insect cells in order to produce recombinant IL-18BP. For expression in yeast cells, the DNA coding for IL-18BP (Example 6) is cut out and inserted into expression vectors suitable for transfection of yeast cells. For expression in insect cells, a DNA coding for IL-18BP is inserted into baculovirus and the insect cells are infected with said recombinant baculovirus. For expression in E. coli, 5 the DNA coding for IL-18BP is subjected to site directed mutagenesis with appropriate oligonucleotides, so that an initiation ATG codon is inserted just prior to the first codon of mature IL-18BP. Alternatively, such DNA can be prepared by PCR with suitable sense and antisense primers. The resulting cDNA constructs are then inserted into appropriately constructed prokaryotic expression vectors by techniques well known in the art (23).
10

15 **Example 10: Construction of adeno-associated expression vector for in vivo expression of IL-18BPa**

A functional gene coding for IL-18BPa is constructed based on plasmid pcDNA3 (Invitrogen, San Diego CA). The IL-18BP cDNA with a Kozak consensus sequence at the 5' end is ligated into the Xba I site of pcDNA3 in a way that destroys the restriction site. New 20 Xba I sites are inserted by site-directed mutagenesis before the neomycin cassette (base 2151 of the original pcDNA3 sequence) and after the SV40 polyadenylation signal (base 3372 of the original pcDNA3 sequence). This construct is then cut with Xba I and the resulting 4.7 kb minigen is inserted at the Xba I site of plasmid psub201 as described (Snyder et al, 1996, Current Protocols in Human Genetics, Chapters 12.1.1-12.1.17, John Wiley & Sons). The 25 resulting recombinant plasmid is cotransfected with the helper AAV plasmid pAAV/Ad into human T293 cells. The cultures are then infected with adenovirus as a helper virus and the cells are collected after 48-60 hours of incubation. The cells are subjected to 3 freeze-thaw cycles, cell debris is removed by centrifugation, and the supernatant is brought to 33% saturation with ammonium sulfate. The mixture is then centrifuged and rAAV is precipitated 30 from the supernatant by bringing the ammonium sulfate to 50% saturation. The virus is

further purified by CsCl, dialyzed and finally heated for 15 min at 56°C to destroy any adenovirus.

Example 11: Construction of recombinant fusion proteins of IL-18BP

The production of proteins comprising IL-18BP fused to the constant region of IgG2 heavy chain may be carried out as follows: the DNA of IL-18BP is subjected to site-directed mutagenesis with appropriate oligonucleotides so that a unique restriction site is introduced immediately before and after the coding sequences. A plasmid bearing the constant region of IgG2 heavy chain, e.g. pRKCO42Fc1(6) is subjected to similar site-directed mutagenesis to introduce the same unique restriction site as close as possible to Asp 216 of IgG1 heavy chain in a way that allows translation in phase of the fused protein. A dsDNA fragment, consisting of 5' non-translated sequences and encoding for IL-18BP is prepared by digestion at the unique restriction sites or alternatively by PCR with appropriately designed primers. The mutated pRKCD42Fc1 is similarly digested to generate a large fragment containing the plasmid and the IgG1 sequences. The two fragments are then ligated to generate a new plasmid, encoding a polypeptide precursor consisting of IL-18BP and about 227 C-terminal amino acids of IgG1 heavy chain (hinge region and CH2 and CH3 domains). The DNA encoding the fused proteins may be isolated from the plasmid by digestion with appropriate restriction enzymes and then inserted into efficient prokaryotic or eukaryotic expression vectors.

20 Example 12 : Production of chemically modified IL-18BPs

In order to increase the half-life of the IL-18BPs in plasma, IL-18BPs which are chemically modified with polyethylene glycol (PEG) may be made. The modification may be done by cross linking PEG to a cysteine residue of the IL-18BP molecules. Mutant IL-18BPs may be constructed which contain an extra cysteine residue at the amino terminus, glycosylation sites, and the carboxyl terminus of each IL-18BP. The mutagenesis may be carried out by PCR using oligonucleotides containing the desired mutation. These mutant

proteins are expressed in the usual manner as well known in the art. Pegylation of these proteins will be carried out and the activity will be assessed.

Example 13: Preparation of polyclonal antibodies to IL-18BP

Rabbits were initially injected subcutaneously with 5 µg of a pure preparation of the urinary IL-18BP, emulsified in complete Freund's adjuvant. Three weeks later, they were injected again subcutaneously with 5 µg of the IL-18BP preparation in incomplete Freund's adjuvant. Two additional injections of IL-18BP as solution in PBS were given at 10 day intervals. The rabbits were bled 10 days after the last immunization. The development of antibody level was followed by a radioimmunoassay. ^{125}I -labeled IL-18BP (166,000 cpm) was mixed with various dilutions (1:50, 1:500, 1:5,000 and 1:50,000) of the rabbit serum. A suspension of protein-G agarose beads (20 µl, Pharmacia) was added in a total volume of 200 µl. The mixture was left for 1 hour at room temperature, the beads were then washed 3 times and bound radioactivity was counted. Rabbit antiserum to human leptin was used as a negative control. The titer of the IL-18R antiserum was between 1:500 and 1:5000, while that of the negative control was less than 1:50.

EXAMPLE 14: Preparation of monoclonal antibodies to IL-18BP

Female Balb/C mice (3 months old) are first injected with 2 µg purified IL-18BP in an emulsion of complete Freund's adjuvant, and three weeks later, subcutaneously in incomplete Freund's adjuvant. Three additional injections are given at 10 day intervals, subcutaneously in PBS. Final boosts are given intraperitoneally 4 and 3 days before the fusion to the mouse showing the highest binding titer as determined by IRIA (see below). Fusion is performed using NSO/1 myeloma cell line and lymphocytes prepared from both the spleen and lymph nodes of the animal as fusion partners. The fused cells are distributed into microculture plates and the hybridomas are selected in DMEM supplemented with HAT and 25% horse serum. Hybridomas that are found to produce antibodies to IL-18BP are subcloned by the limiting dilution method and injected into Balb/C mice that had been primed with pristane for the production of ascites. The isotypes of the antibodies are defined with the use of a commercially available ELISA kit (Amersham, UK).

The screening of hybridomas producing anti-IL-18BP monoclonal antibodies is performed as follows: Hybridoma supernatants are tested for the presence of anti-IL-18BP antibodies by an inverted solid phase radioimmunoassay (IRIA). ELISA plates (Dynatech Laboratories, Alexandria, VA) are coated with Talon-purified IL-18BPa-His₆ (10 µg/ml, 5 100 µl/well). Following overnight incubation at 4°C, the plates are washed twice with PBS containing BSA (0.5%) and Tween 20 (0.05%) and blocked in washing solution for at least 2 hrs at 37°C. Hybridoma culture supernatants (100 µl/well) are added and the plates are incubated for 4 hrs at 37°C. The plates are washed 3 times and a conjugate of goat-anti-mouse horseradish peroxidase (HRP, Jackson Labs, 1:10,000, 100 µl/well) is added 10 for 2 hrs at room temperature. The plates are washed 4 times and the color is developed by ABTS (2,2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid, Sigma) with H₂O₂ as a substrate. The plates are read by an automatic ELISA reader. Samples giving OD that are at least 5 times higher than the negative control value are considered positive.

EXAMPLE 15: Affinity chromatography of IL-18BP with monoclonal antibodies

15 Antibodies against IL-18BP are utilized for the purification of IL-18BP by affinity chromatography. Ascitic fluid containing the monoclonal antibody secreted by the hybridoma is purified by ammonium sulfate precipitation at 50% saturation followed by extensive dialysis against PBS. About 10 mg of immunoglobulins are bound to 1 ml Affigel 10 (BioRad USA), as specified by the manufacturer.

20 250 ml of human urinary proteins (equivalent to 250 l of crude urine) are loaded on 0.5 ml of the anti IL-18BP antibody column at 4°C at a flow rate of 0.25 ml/min. The column is washed with PBS until no protein is detected in the washings. IL-18BP is eluted by 25 mM citric acid buffer, pH 2.2 (8 x 1 column volume fractions) and immediately neutralized by 1 M Na₂CO₃. Further purification of this preparation is obtained by size exclusion 25 chromatography.

EXAMPLE 16: ELISA test

Microtiter plates (Dynatech or Maxisorb, by Nunc) are coated with anti-IL-18BP monoclonal antibody (serum free hybridoma supernatant or ascitic fluid immunoglobulins) overnight at 4°C. The plates are washed with PBS containing BSA (0.5%) and Tween 20 (0.05%) and blocked in the same solution for at least 2 hrs at 37°C. The tested samples are diluted in the blocking solution and added to the wells (100 µl/well) for 4 hrs at 37°C. The plates are then washed 3 times with PBS containing Tween 20 (0.05%) followed by the addition of rabbit anti-IL-18BP serum (1:1000, 100 µl/well) for further incubation overnight at 4°C. The plates are washed 3 times and a conjugate of goat-anti-rabbit horseradish peroxidase (HRP, Jackson Labs, 1:10,000, 100 µl/well) was added for 2 hrs at room temperature. The plates were washed 4 times and the color is developed by ABTS (2,2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid, Sigma) with H₂O₂ as a substrate. The plates are read by an automatic ELISA reader.

EXAMPLE 17 : Non-glycosylated human IL-18BP is biologically active.

Purified recombinant IL-18BPa was tested for its ability to inhibit the biological activity of IL-18. IL-18BPa inhibited in a dose dependent manner the IFN-γ inducing activity of human and mouse IL-18 in murine splenocytes, PBMC and the human KG-1 cell line (Fig. 9).

Purified IL-18BPa having an His₆ tag at the C-terminus (1.5 µg, 50 µl) was adjusted to pH 7.5 and mixed with N-glycosidase F (3 µl, 500,000 U/ml, PNGase F, New England Biolabs). The mixture was incubated for 24 h at 37°C under non-denaturing conditions. Aliquots from the sample and from undigested IL-18BP-His₆ were analyzed by SDS-PAGE under non-reducing conditions followed by immunoblotting with antibodies to IL-18PB. It was found that the ~40 kD band of IL-18BP-His₆ disappeared in the PNGase-treated fraction and a new ~20 kD band was obtained. The molecular mass of the product and the specificity of PNGase F indicated that IL-18BP-His₆ was fully deglycosylated.

The PNGase-treated fraction, undigested IL-18BP-His₆ and control sample containing PNGase in buffer were absorbed separately on Talon beads, washed with phosphate buffer and eluted with imidazole (100 mM). The eluted fractions were subjected to bioassay using human IL-18 (20 ng/ml), LPS (2 µg/ml) and murine splenocytes. The 5 results are shown in the following table:

<u>Sample</u>	<u>IFN-γ (ng/ml)</u>
Control	7.5
Non-digested IL-18BP-His ₆	0
PNGase-treated IL-18BP-His ₆	0

Therefore, it is concluded that deglycosylated IL-18BP is biologically active as a modulator of IL-18 activity.

The foregoing description of the specific embodiments reveal the general nature of 10 the invention so that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of 15 description and not of limitation.

References

1. Anderson, D.M., et al., *A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.* Nature, 1997. 390(6656): p. 175-179.
2. Bollon, D. P., et al. (1980) *J. Clin. Hematol. Oncol.* 10:39-48.
- 5 3. Botstein, D., et al. (1982) Miami Wint. Symp. 19:265-274.
4. Broach, J. R., in "The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance", Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 445-470 (1981).
5. Broach, J. R., (1982) *Cell* 28:203-204.
- 10 6. Byrn R. A. et al., 1990, *Nature* (London) 344:667-670.
7. Car, B. D., V. M. Eng, B. Schnyder, L. Ozmen, S. Huang, P. Gallay, D. Heumann, M. Aguet, and B. Ryffel. 1994. Interferon gamma receptor deficient mice are resistant to endotoxic shock. *J. Exp. Med.* 179:1437-44 issn: 0022-1007.
- 15 8. Chater, K. F. et al., in "Sixth International Symposium on Actinomycetales Biology", Akademiai Kaido, Budapest, Hungary (1986), pp. 45-54).
9. Conti, B., J. W. Jahng, C. Tinti, J. H. Son, and T. H. Joh. 1997. Induction of interferon-gamma inducing factor in the adrenal cortex. *J. Biol. Chem.* 272:2035-2037.
10. Dao, T., K. Ohashi, T. Kayano, M. Kurimoto, and H. Okamura. 1996. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. *Cell-Immunol.* 173:230-5 issn: 0008-8749.
- 20 11. Engelmann, H., D. Aderka, M. Rubinstein, D. Rotman, and D. Wallach. 1989. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. *J. Biol. Chem.* 264:11974-11980.

12. Engelmann, H., D. Novick, and D. Wallach. 1990. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. *J. Biol. Chem.* **265**:1531-1536.

5 13. Fantuzzi, G., et al., *IL-18 regulation of IFN- γ production and cell proliferation as revealed in interleukin-1 β converting enzyme-deficient mice*. Blood, 1998. **91**: p. 2118-2125.

14. Gryczan, T., "The Molecular Biology of the Bacilli", Academic Press, NY (1982), pp. 307-329).

10 15. Gutkind, J.S., et al., *A novel c-fgr exon utilized in Epstein-Barr virus-infected B lymphocytes but not in normal monocytes*. Molec. Cell. Biol., 1991. **11**: p. 1500-1507.

16. Heremans, H., J. Van Damme, C. Dillen, R. Dijkmans, and A. Billiau. 1990. Interferon gamma, a mediator of lethal lipopolysaccharide-induced Shwartzman-like shock reactions in mice. *J. Exp. Med.* **171**:1853-69 issn: 0022-1007.

15 17. Izaki, K. (1978) *Jpn. J. Bacteriol.* **33**:729-742).

18. John, J. F., et al. (1986) *Rev. Infect. Dis.* **8**:693-704).

19. Kendall, K. J. et al. (1987) *J. Bacteriol.* **169**:4177-4183).

20. Kohno, K., J. Kataoka, T. Ohtsuki, Y. Suemoto, I. Okamoto, M. Usui, M. Ikeda, and M. Kurimoto. 1997. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. *J. Immunol.* **158**:1541-1550.

21. Maliszewski, C. R., T. A. Sato, T. Vanden Bos, S. Waugh, S. K. Dower, J. Slack, M. P. Beckmann, and K. H. Grabstein. 1990. Cytokine receptors and B cell functions. I. Recombinant soluble receptors specifically inhibit IL-1- and IL-4-induced B cell activities in vitro. *J. Immunol.* **144**:3028-3033.

22. Maniatis, T., in "Cell Biology: A Comprehensive Treatise, Vol. 3: Gene Expression", Academic Press, NY, pp. 563-608 (1980).

23. Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1982.

5 24. Micallef, M. J., T. Ohtsuki, K. Kohno, F. Tanabe, S. Ushio, M. Namba, T. Tanimoto, K. Torigoe, M. Fujii, M. Ikeda, S. Fukuda, and M. Kurimoto. 1996. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. *Eur-J-Immunol* 26:1647-51 issn: 0014-2980.

10 25. Mizushima, S. and Nagata, S. (1990) pEF-BOS, a powerful mammalian expression vector. *Nucleic Acid Res.* 18:5322-5328.

26. Nakamura, K., H. Okamura, K. Nagata, T. Komatsu, and T. Tamura. 1993. Purification of a factor which provides a costimulatory signal for gamma interferon production. *Infect-Immun* 61:64-70 issn: 0019-9567.

15 27. Nakamura, K., H. Okamura, M. Wada, K. Nagata, and T. Tamura. 1989. Endotoxin-induced serum factor that stimulates gamma interferon production. *Infect-Immun* 57:590-5 issn: 0019-9567.

28. Novick, D., B. Cohen, and M. Rubinstein. 1994. The Human Interferon alpha/beta Receptor - Characterization and Molecular Cloning. *Cell* 77:391-400.

20 29. Novick, D., B. Cohen, and M. Rubinstein. 1992. Soluble Interferon-alpha Receptor Molecules Are Present in Body Fluids. *FEBS Lett* 314:445-448.

30. Novick, D., H. Engelmann, D. Wallach, and M. Rubinstein. 1989. Soluble cytokine receptors are present in normal human urine. *J. Exp. Med.* 170:1409-1414.

25 31. Okamura, H., H. Tsutsui, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, K. Akita, M. Namba, F. Tanabe, K. Konishi,

S. Fukuda, and M. Kurimoto. 1995. Cloning of a new cytokine that induces IFN-gamma production by T cells. *Nature* 378:88-91.

32. Rothe, H., N. A. Jenkins, N. G. Copeland, and H. Kolb. 1997. Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2. *J-Clin-Invest* 99:469-74 issn: 0021-9738.

5

33. Sambrook, J., E.F. Fritsch, and M. T., *Molecular Cloning: A laboratory manual*. 2nd ed. ed. 1989, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory.

34. Simonet, W.S., et al., *Osteoprotegerin: a novel secreted protein involved in the regulation of bone density*. Cell, 1997. 89(2): p. 309-319.

10 35. Sompayrac, L.H. and K.L. Danna, *Efficient infection of monkey cells with DNA of simian virus 40*. Proc. Nat'l. Acad. Sci. USA, 1981. 78: p. 7575-7578.

36. Sparks, C.A., et al., *Assignment of the nuclear mitotic apparatus protein NuMA gene to human chromosome 11q13*. Genomics, 1993. 17: p. 222-224.

37. Tsutsui, H., K. Nakanishi, K. Matsui, K. Higashino, H. Okamura, Y. Miyazawa, and K. Kaneda. 1996. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. *J. Immunol.* 157:3967-73 issn: 0022-1767.

15

38. Ushio, S., M. Namba, T. Okura, K. Hattori, Y. Nukada, K. Akita, F. Tanabe, K. Konishi, M. Micallef, M. Fujii, K. Torigoe, T. Tanimoto, S. Fukuda, M. Ikeda, H. Okamura, and M. Kurimoto. 1996. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. *J. Immunol.* 156:4274-4279.34. Okayama, H. and Berg, P. (1983) A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells. *Mol. Cell. Biol.* 3:280-289.

20

39. Yasuda, H., et al., *Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro*. Endocrinology, 1998. 139: p. 1329-1337.

25

SEQUENCE LISTING

<110> Novick, Daniela
Dinarello, Charles
Rubinstein, Menachem
Kim, Soo Hyun
Yeda Research and Development Co. Ltd.

<120> Interleukin-18 Binding Proteins, their Preparation and
Use

<130> IL-18 Rubinstein

<140>
<141>

<150> 125463
<151> 1998-07-22

<150> 122134
<151> 1997-11-06

<150> 121269
<151> 1997-09-29

<150> 121639
<151> 1997-08-27

<150> 121554
<151> 1997-08-14

<160> 10

<170> PatentIn Ver. 2.0

<210> 1
<211> 1348
<212> DNA
<213> Homo sapiens

<400> 1
gagaagagga cgttgtcaca gataaagac caggctcacc agtcctgac gcatgcata 60
tgaccatgag acacaactgg acaccagacc tcagccctt gtgggtctg ctcctgttg 120
cccacgtcgta cactctcctg gtcagagcca cacctgtctc gcagaccacc acagctgcca 180
ctgcctcagt tagaagcaca aaggaccct gccccctccca gcccccaatgt ttcccagcag 240
ctaagcaatgttccagcattt gaagtgcacct ggccagaggt ggaagtgcata ctgaatggaa 300
cgctgacgtt atcctgttg gcctgcagcc gcttcccaat cttcagcatc ctctactggc 360
tggggcaatgg ttccttcatt gagcacatcc caggccgact gtgggagggg agcaccagcc 420

gggAACGTGG ~~g~~agcacagg~~t~~ acgcagctgt gcaaggc~~c~~tt ggtgctggag cagctgaccc 480
 ctgc~~c~~ctg~~c~~a cagcaccaac ttctcc~~t~~gtg tgctcg~~t~~gga ccctgaacag gttgtcc~~c~~gc 540
 gtcacgtc~~c~~gt cctggccc~~a~~g ctctggg~~c~~tg ggctgagg~~g~~g aac~~c~~ttgccc cccaccca~~a~~g 600
 aagccctg~~c~~cc aaccc~~c~~ccac agcag~~t~~ccac agcagcagg~~g~~ ttaagactca gcacagg~~g~~cc 660
 agcagcag~~c~~ca caac~~c~~ttg~~c~~ac caga~~g~~ttgg gtcctac~~t~~ct tg~~t~~ac~~c~~t~~g~~ga gtgaacag~~t~~c 720
 cctgactg~~c~~cc t~~t~~tagg~~c~~tc~~g~~ g~~t~~ggatgc~~g~~c aacacacccc ctc~~c~~ttct~~c~~t~~c~~ g~~c~~tttggg~~t~~c 780
 ccttctct~~c~~ca ccaaatt~~c~~aa actccattcc cacctac~~c~~ta gaaaatcaca gcctcc~~c~~ttat 840
 aatgcctc~~c~~t cctcctg~~c~~ca ttctctct~~c~~cc acctatcc~~c~~at tagcctc~~c~~ct aacgtc~~c~~ctac 900
 tcctcacact g~~c~~tctact~~c~~gc tcagaaac~~c~~ca ccaagact~~t~~gt tgatgc~~c~~tt~~a~~ g~~c~~cttgc~~a~~c~~t~~ 960
 ccagggcc~~c~~ct ac~~c~~tgc~~a~~ttt cccacat~~c~~gac tttctg~~g~~gaag cctcc~~c~~act attcttg~~c~~tt 1020
 ttcccagaca g~~c~~tccc~~c~~act~~c~~ ccat~~t~~ct~~c~~t~~c~~ g~~c~~tcat~~t~~tag tccc~~c~~gt~~c~~tt~~c~~ ctcaccg~~g~~ccc 1080
 cagcaggg~~g~~ga ac~~c~~g~~c~~tca~~a~~g~~c~~ ctgg~~t~~gaaa tgctgc~~c~~ct~~c~~t~~c~~ tc~~a~~gt~~g~~aa~~g~~t catcc~~c~~~~c~~ttt 1140
 cagctct~~c~~gc c~~c~~g~~c~~att~~c~~tc~~g~~ agactt~~c~~cta t~~c~~tt~~c~~gt~~g~~ct~~c~~ g~~t~~at~~g~~tttt t~~t~~tttcccc~~c~~ 1200
 ttca~~c~~ctct~~c~~aa t~~g~~gact~~g~~tt~~c~~ caggg~~a~~agg~~g~~ atgggg~~c~~ac~~c~~ cagctgc~~t~~tc~~c~~ g~~g~~atcc~~c~~ac~~c~~ 1260
 t~~g~~tat~~c~~tg~~t~~g~~t~~ ~~t~~catcccc~~c~~ac atgggtc~~c~~tc~~c~~ ataaagg~~a~~tt~~c~~aat~~g~~ga aaaaaaaaaa 1320
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1348

<210> 2

<211> 192

<212> PRT

<213> Homo sapiens

<220>

<221> SIGNAL

<222> (1)...(28)

<400> 2

Met	Arg	His	Asn	Trp	Thr	Pro	Asp	Leu	Ser	Pro	Leu	Trp	Val	Leu	Leu
1															15

Leu	Cys	Ala	His	Val	Val	Thr	Leu	Leu	Val	Arg	Ala	Thr	Pro	Val	Ser
															30
				20				25							

Gln	Thr	Thr	Thr	Ala	Ala	Thr	Ala	Ser	Val	Arg	Ser	Thr	Lys	Asp	Pro
															45
				35				40							

Cys	Pro	Ser	Gln	Pro	Pro	Val	Phe	Pro	Ala	Ala	Lys	Gln	Cys	Pro	Ala
															60
				50				55							

Leu	Glu	Val	Thr	Trp	Pro	Glu	Val	Glu	Val	Pro	Leu	Asn	Gly	Thr	Leu
															80
				65				70			75				

Ser	Leu	Ser	Cys	Val	Ala	Cys	Ser	Arg	Phe	Pro	Asn	Phe	Ser	Ile	Leu
															95
				85				90							

Tyr	Trp	Leu	Gly	Asn	Gly	Ser	Phe	Ile	Glu	His	Leu	Pro	Gly	Arg	Leu
															110
				100				105							

Trp Glu Gly Ser Thr Ser Arg Glu Arg Gly Ser Thr Gly Thr Gln Leu
 115 120 125

Cys Lys Ala Leu Val Leu Glu Gln Leu Thr Pro Ala Leu His Ser Thr
 130 135 140

Asn Phe Ser Cys Val Leu Val Asp Pro Glu Gln Val Val Gln Arg His
 145 150 155 160

Val Val Leu Ala Gln Leu Trp Ala Gly Leu Arg Ala Thr Leu Pro Pro
 165 170 175

Thr Gln Glu Ala Leu Pro Ser Ser His Ser Ser Pro Gln Gln Gln Gly
 180 185 190

<210> 3
 <211> 1038
 <212> DNA
 <213> Homo sapiens

<400> 3
 gagaagagga cgttgtcaca gataaagagc caggctcacc agtcctgac gcatgcata 60
 tgaccatgag acacaactgg acaccagacc tcagccctt gtgggtcctg ctccgtgtg 120
 cccacgtcggt cactctcctg gtcagagcca cacctgtctc gcagaccacc acagctgcca 180
 ctgcctcagt tagaaggcaca aaggccccct gccccccttca gcccccaactg ttcccagcag 240
 ctaaggcgtg tccagcatgg gaagtgcacct ggccagaggt ggaagtgcata ctgagctggg 300
 ctgagggcaa ctttgccttca caccctaaagaa gccctgcctt ccagccacag cagtccacag 360
 cagcagggtt aagactcagc acagggccag cagcagcaca accttgacca gagcttgggt 420
 cctacctgtc tacctggagt gaacagttttc tgactgcctg taggctgcgt ggatgcgcaa 480
 cacacccctt ctttctctgc tttgggtttttt ttctctcacc aaattcaaaac tccatttttttca 540
 cctaccta gataatcacatc ctttgccttataa tgccctcctcc tcctgcattt ctctctccac 600
 ctatccatta gccttcctaa cgtccctactc ctcacactgc tctactgctc agaaaccacc 660
 aagactgttg atgccttagc cttgcactcc agggccctac ctgcattttcc ccatgactt 720
 tctgaaagcc tcccaacttat tcttgcctttt cccagacagc tcccaacttcc atgtctctgc 780
 tcatttagtc ccgtttttccctt caccggccca gcaaggggaaac gctcaagccctt ggttggaaatg 840
 ctgccttccttca agtgaagtca tccttccttca gctctggcccg cattctgcag acttcctatc 900
 ttctgtgtgt atgtttttttttttt tttcccccctt cactctaattg gactgttcca gggaaaggat 960
 gggggcacca gctgcttcgg atccacactg tatctgtgtc atccccacat gggtcctcat 1020
 aaaggattat tcaatggaa 1038

<210> 4
 <211> 113
 <212> PRT
 <213> Homo sapiens

<220>

<221> SIGNAL

<222> (1)..(28)

<400> 4

Met	Arg	His	Asn	Trp	Thr	Pro	Asp	Leu	Ser	Pro	Leu	Trp	Val	Leu	Leu
1															15

Leu	Cys	Ala	His	Val	Val	Thr	Leu	Leu	Val	Arg	Ala	Thr	Pro	Val	Ser
															30
20							25								

Gln	Thr	Thr	Thr	Ala	Ala	Thr	Ala	Ser	Val	Arg	Ser	Thr	Lys	Asp	Pro
															45
35							40								

Cys	Pro	Ser	Gln	Pro	Pro	Val	Phe	Pro	Ala	Ala	Lys	Gln	Cys	Pro	Ala
															50
50							55								60

Leu	Glu	Vai	Thr	Trp	Pro	Glu	Val	Glu	Val	Pro	Leu	Ser	Trp	Ala	Glu
															65
65							70								80

Gly	Asn	Leu	Ala	Pro	His	Pro	Arg	Ser	Pro	Ala	Leu	Gln	Pro	Gln	Gln
															85
															90

Ser	Thr	Ala	Ala	Gly	Leu	Arg	Leu	Ser	Thr	Gly	Pro	Ala	Ala	Ala	Gln
															100
															105

Pro

<210> 5

<211> 7063

<212> DNA

<213> Homo sapiens

<400> 5

gaattcgcgg	ccgcgtcgac	gccagagggg	ctaggatgag	agacagagggg	tgtgatggtg	60
ggtgctggga	aatgtaccccg	accttggggc	tggtggtctgg	gggagtggtgg	agcctggaa	120
aggccaggat	gtggacggac	tggtatggca	ttagcctga	agtggtccaa	cttggggttc	180
cccagtgcct	aggaaaagtgg	tccccttgaa	tgtcagtgtc	aaggtaagg	aggaaggcaga	240
tgcctgttca	tatggaaaca	aagacctggc	tgtgaagagg	ggaggcggac	accaaagtcc	300
tgcacacttgg	gcggggacaga	attgatctgt	gagagactca	tctagttcat	acccttaggt	360
accctggggg	tggcatgggg	gtagattaga	gatcccagtc	tggtatccctc	tggagagtag	420
gagtcccagg	agctgaaggt	ttctggccac	tgaactttgg	ctaaagcaga	ggtgtcacag	480
ctgctcaaga	ttccctgggtt	aaaaagtgaa	agtgaaataag	agggtcgggg	cagtgccttc	540
ccagaaggat	tgctcggcat	cctgcccttc	ccagaaggca	ctctggtgct	gaagagagca	600
ctgcctccct	gtgtgactgg	gtgagtcct	attctctctt	tgggtctcaa	ttttgccttc	660

cctaataatgaag gggtaagatt ggacttagtta aaccaatttgt ggtcatgaga 720
 gctgggggg ggaaggattt tcacttgacc ccccccagctc ttttctaaag tgctgaaaga 780
 gctccaggct atgctacggg aggagaagcc agtacttgag gaaaagccag ctactgagaa 840
 aaagcgggag tggtttacca ttctccccc ccacccctca ccagagaaga ggacggttgc 900
 acacataaaag agccaggctc accagctcc gacgcatgca tcatgaccat gagacacaac 960
 tggacaccag acctcagccc ttgtgggtc ctgtctctgt gtgcccacgt cgtcacccctc 1020
 ctggtcagag ccacacctgt ctcgcagacc accacagctg ccactgcctc agttagaaac 1080
 acaaaggacc cctgccccctc ccagccccca gtgttcccag cagctaaagca gtgtccagca 1140
 ctggaaatgaa cctggccaga ggtggaagtg ccactgaatg gaacgctgag cttatccgt 1200
 gtggcctgca gccgcttccc caacttcagc atcctctact ggctgggcaa tggttccctc 1260
 attgagcacc tccccaggccg actgtggag gggagcacca gccgggaacg tggagcaca 1320
 ggtacgcagc tgtcaagggc cttgggtctg gacgactgaa cccctgcct gcacagzacc 1380
 aacttccctt gtgtgctcg ggaccctgaa caggttgcctc agcgtcacgt cgtccctggcc 1440
 cagctczzgg tggaggagccc aaggagagcc cttcaggaaac aggaggagct cgtctccat 1500
 atgtggggag gaaagggtgg gctctgccag agcagccctgta gactaatgc ccagcaatcc 1560
 tcaaggctcag ccagacaaaaa aggaacttag gtcttggca gaggaggtgt agcctgggc 1620
 aaaatgtatga gatgtccctc ttcccttg cctgatcctt gtctgccttc acttccctag 1680
 gctgggtcgaa gggcaacccctt gccccccacc caagaagcccc tggccctccag ccacagcgt 1740
 ccacacgcg agggttaaga cttagcacag gggccagcgc agcacaacct tgaccaagc 1800
 ttggggccata cctgtctacc tggagtgaac agtccctgac tggctgttagg ctgcgtggat 1860
 ggcacacaca cccccccttctt ctgtgttttgg tggcccttctt ctcaccaaat tcaaaccicca 1920
 ttccccaccta cctagaaaaat cacagcctcc ttataatgcc tccctccctt gccattctt 1980
 ctccacccat ccattagcc tccaaacgtc ctactccctca cactgctcta ctgctcagaa 2040
 accaccaaga ctgttgatgc cttagcccttgc cactccaggcccttccatgc atttccacaca 2100
 tgactttctg gaagccccc aactattctt gtttttccca gacagccccc actccctatgt 2160
 ctctgcctat ttagtcccgt ctccctcacc gccccagcag gggAACGCTC aagcctgggt 2220
 gaaatgtcgc ctccctcagtg aagtcatcctt ttttgcctc tggccgcatt ctgcagactt 2280
 cctatccctg tgctgtatgt ttttttttccctact ctaatggact gttccaggaa 2340
 agggatccccgg gcaagcagctg ctccggatcc acactgtatc tggctcatcc ccacatgggt 2400
 cctcataaaag gattattcaa tggaggccatc ctgacatctg ttcatggatg ctccatggcc 2460
 actcccaagga actttgcctg tcccacgagg gagtatggaa gagatggact gccacacaga 2520
 agctgaagac aacacctgtc tcagggaaac acaggcgctt gaaaaagaaaa agagagaaca 2580
 gcccataatgaa ctccccggga gcaagggcca ctaatggaga gtggaaagag cctggaaaga 2640
 tgtggccctca gaaaaggaa tgagagaaatg gaggtggat ggaagactca gcaggaacaa 2700
 ggttaggcctt aaagagccta tattccctt tttcccacac cgatcaagtc aactcaatgc 2760
 tcacgcaga aaaaatagact ttatccatca gtaataacat ttagaaaaaga tccatccccg 2820
 gcccataaaaa accttcccat cactccaaat cccacccctc tgcaagtcg gggaaaggtag 2880
 ggtgtgagct gctgtgtggaa gctgtccccc aaccccaactc ctgagacaca gggcccttcc 2940
 gtccctggaa agagcatccctt ctggcaggctg ctcccccaccag gtcagaccca gtccctggact 3000
 tcaagactgaa gggccccctgc tggcccccagc caccaggaca gcaggaacca gggcttactc 3060
 ctcttatggt cccttctaga tccagaggct aagaggaaga ctggccaggc ccaaggaccc 3120
 agccatcaaa accagcctca aatctggatgg ttagggagaa gtgactttgc tttaagaaaa 3180
 aaggaggcaa ggttagggaga gcccacac tggccatgtc ccaggcccccc tggccagct 3240
 cccgagaaggcc gcaactgtaaag gaccaggccatc caggccagggg tggccggcagg catcaatgtc 3300
 tcttaggggtt tggctactgt tggccctggaa gctgagagaa ggcactgaga gggacagtag 3360
 gcccggggacc aggtgacggc agcatcgaaaa acacagggtgg ggcacttcac tggactggc 3420
 ctcttagtgc ttgcctgaa agagacacag tcacatggcc agatgagaac ttgcgatact 3480
 agcctgcacc cactggctgg gaagatctt tccctgcctt acggccctgt ctggatcccc 3540

tccccctgtga gccccaggt tatcagtgc tggctgtgcc tgagcagctc tgggtgctct 3600
 ccatgagaat gggccatct gtcttcctc cttggagagg agctaccagg acagggacac 3660
 ctcttacccc acaccctcca gcagcctggc gtggcccat cttggatgct acttgggtggg 3720
 gcggtctggg gggtgcctat gctctcatcg ggtttccctc ccccatctg ccagtgcctc 3780
 taccttgcctc ttggctcgag gggtggcacc aatggcggca gcagtggcgg cgctggctg 3840
 ggtggggca atgcgcggag aacggcgggt tccactgcga gtgttgggg aaggcttgg 3900
 caggcccttc ttgaggctc cccgcccag aaggctgttc cctagcttct tgggtgtgtt 3960
 gagggatgtcg aaggccatcg actggcgccg gtcagcctgc aaggaaggc tgcagaccg 4020
 ggagacccaa tgctgcctc ccaggccagc gtgtgtgc acgctgtacc agcaaggctcc 4080
 cgcaggccg tcgcttcata ccccttcagc cccagctca cctgttttagt agaagctgg 4140
 gctgtttct tctggccctc agtagtgctc tgggtgcctc cttcatgtcg gtctcgggg 4200
 gtcatggggc gtggaaaca gctgggtggcc ttcttagact atggagaaga ggacagttag 4260
 gcagacagta gcaagaggag tcacatctga agccagggtt cttgtccctc cagagctgag 4320
 tggaccttgt aagtcaacgt gcaacctgtc ccccttccca actctggcc agatcettcc 4380
 ctcccacaca gatccatcc atgggtcagg cccttggaga gaggaaaga gagggggaaag 4440
 tgagggaaagg agagagaagg ctcccttag tccttggta gctggccctg acctgagcac 4500
 agtgctggag taacacccag gagccacccgc gcctacctca cggatccag ggcctgg 4560
 gggcctctagg gagacccgtt tgcgtgtcg cccgggtgggt atgcccattgc cctccggctat 4620
 ctggattggc tgcgtgtcg ctggcgccag ggatcttgc gggtctccag tttcatctc 4680
 ctcatctgtg atgggtccca ggctcaggga aggctgcattt ggtggaaagag gtggtcagtg 4740
 gaccatagct gatggagat ggaggaggac ctggggctgt tccagaactc tacactcgcc 4800
 cgacacttat gtcgggacc ctccctgcct acgaggtaga aagacacaag cctcccttcc 4860
 tggatctgtt tctacctaag ccctggcaaa atggcacaag cagtgcagtc ctgaccagat 4920
 tcctctctga gtcctgcct acccccaggc acttcacccctc tgagtgcctt ccagctgtct 4980
 gttccacactg gaacatgaga aggtcacccctt cggccagtc gtgatccagg 5040
 gcccattgtc tggcgttgc tcaaggctaga tcaaggctgtt ggattccaag gaaggccagg gatggggaggc 5100
 cctgcacagt gacccctggc ttcacccctgg actccaggaa tagcaggatc tcaatgtgg 5160
 ggggcacact cgttgcgtt gtcgcagtc tcaatgcgg tccagtcat ccagctgtct 5220
 aggctcatcc tggcgttgc ccatgttagaa gtcgttgcctt cctgttgcgg gcaaggaaat 5280
 gggaaacaaat gacccctggc tccacccctgg acctccctggc cctggcatct tgccagcctt 5340
 tgcgtccacc tccacccataa acttgaagcc cggcacacca gtcgttgcattt gtcggcgg 5400
 tgcaggagta cggcacacag actatttcta tccttaggggc ttgttcacca ccttctccct 5460
 ggagagggca gaaagggtca cacgcagaga ctgttactac attttattca cctgccaagg 5520
 cttggtggcc sacacccaga ggaacaaatt aaggaccggg aattaattcc caggggctcc 5580
 ctgggtggccca aaggacaaga gcttccaaga agagtctggc cagcctggcc tttccagcag 5640
 cccatcacccg ctcgagaagg gcatggagga ctcccccacat ctaagtgtca caattgtgt 5700
 gggaatcccc ggccttaac tctggtaag agtgccttca acacagccag ccccttagatg 5760
 ggcaggtaag gaaaggccctg aggctgcagg aaggaggggc aggtggagct ggatggtagc 5820
 aaggaggcca cccttggatt tttaaaaagc ttcccttgc acgttccacc 5880
 ttccagtcta attttgggt atagtaagtc ctcgttagtcc ctcacccctgg agggggccca 5940
 ctggacacccc cggccctggc acgacagac gaaactgcgag tggtggggcg gtagccaggc 6000
 aagctgagca gggctgaggta gtcataatcg ggagaaccca ggcgagctag agactgagta 6060
 gaggagggtgg ctcgcaggct agcctggaa gcaggaggcag accgcgtgtt gtagaaccat 6120
 gagttggcgc tgtctggctc ttccacatct agtcttgcga agacagatg aatctgttgc 6180
 agtgcacatgtt ctcgttgcact gtacagaagc ttccattcc cttccgaagc ctcagatcc 6240
 cacggcacaat ctcgttgcact tccaaaggctt cttaaagtgt gtgtctgcaa 6300
 gaaatggcc ttcgtcgtacat aaggccctcac aagggtggcgc tgatgttgc aagactcttc 6360
 tacgcatttt ttcgttgcact tccatgttgcact tccaaaggctt cttaaagtgt gtgtctgcaa 6420

atcgccccat ttggagatg aagtcaaaag aaataaaagtg actagcccc aatcacactg 6480
 ctaggaagta tcagagctgg ggcttaggcc catgtctcct gactagtca gctcatccc 6540
 cagcctctgc tgtccctcag tccaaacttc cagggccctt accatgtcc agaacttccc 6600
 ccaacttctt ggttagcaggg ggcacccctaa acacacaggt ccccccgtct gtaccagggg 6660
 cccctctcc cctcctccca aacctccccct tcaagatgtg gaaacaaaagg caagggcctg 6720
 cagcctgtca ggcagtcac tgggcagcaa caatgcctc cagctgcatt gggcatgctg 6780
 ggaggcacag gatgggctgc agcttcgcca cgttctctcc ctgcacccctg cacaggctca 6840
 gtgtacgca tggagagaat gctagccctt gtcaggaggc agggatctaa tccttagccct 6900
 gccttttct tcagaagtgc ccttaaccaa gtcactgccc ttttaagac ctctcagctt 6960
 tcccactgta acatggactg gctgctcattc cctccctgtct cctgactgag tgcccagtgc 7020
 aaagatgccc ttgagaggaa gtggaaattt ctgacctgtc gac 7063

<210> 6
 <211> 197
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SIGNAL
 <222> (1)..(28)

<400> 6
 Met Arg His Asn Trp Thr Pro Asp Leu Ser Pro Leu Trp Val Leu Leu
 1 5 10 15

Leu Cys Ala His Val Val Thr Leu Leu Val Arg Ala Thr Pro Val Ser
 20 25 30

Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser Thr Lys Asp Pro
 35 40 45

Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys Gln Cys Pro Ala
 50 55 60

Leu Glu Val Thr Trp Pro Glu Val Glu Val Pro Leu Asn Gly Thr Leu
 65 70 75 80

Ser Leu Ser Cys Val Ala Cys Ser Arg Phe Pro Asn Phe Ser Ile Leu
 85 90 95

Tyr Trp Leu Gly Asn Gly Ser Phe Ile Glu His Leu Pro Gly Arg Leu
 100 105 110

Trp Glu Gly Ser Thr Ser Arg Glu Arg Gly Ser Thr Gly Thr Gln Leu
 115 120 125

Cys Lys Ala Leu Val Leu Glu Gln Leu Thr Pro Ala Leu His Ser Thr
 130 135 140

Asn Phe Ser Cys Val Leu Val Asp Pro Glu Gln Val Val Gln Arg His
 145 150 155 160

Val Val Leu Ala Gln Leu Trp Val Arg Ser Pro Arg Arg Gly Leu Gln
 165 170 175

Glu Gln Glu Glu Leu Cys Phe His Met Trp Gly Gly Lys Gly Gly Leu
 180 185 190

Cys Gin Ser Ser Leu
 195

<210> 7

<211> 1360

<212> DNA

<213> Homo sapiens

<400> 7

gcggccgcgt cgaccacgca gctaaacaca gctaacttga gtcttgagc tcctaaagg 60
 aagcttctgg aaaggaagc tcttcaggac ctcttaggag ccaaagaaga ggacgttgc 120
 acagataaaag agccaggctc accagctct gacgcatgca tcatgaccat gagacacaac 180
 tggacaccag acctcagccc ttgtgggtc ctgctccgt gtgcccacgt cgtcaactctc 240
 ctggtcagag ccacacctgt ctgcagacc accacagctg ccactgcctc agttagaagc 300
 acaaaggacc cctgcccctc ccagccccca gtgttccca cagctaagca gtgtccagca 360
 ttggaagtga cctggccaga ggtgaaagtg ccactgaatg gaacgctgag cttatccgt 420
 gtggcctgca gccgccttccc caacttcagc atccctctact ggctgggcaa tggttccctc 480
 attgagcacc tcccaggccg actgtgggag gggagcacca gccggaaacg tgggagcaca 540
 ggctgggcgt agggcaacct tgccccccac ccaagaagcc ctgcccctca gccacagcag 600
 tccacagcag cagggttaag actcagcaca gggccagcag cagcacaacc ttgaccagag 660
 cttgggtccct acctgtctac ctggagtgaa cagtccttga ctgcctgtgactgcgttgg 720
 tgcccaacac accccctctc tctctgtttt gggcccttcc tctcaccaaa ttcaaactcc 780
 attcccaccc acctagaaaa tcacagcctc ctataaatgc ctccctctcc tgccattctc 840
 tctccaccta tccatttagcc ttcctaacgt cctactctc acactgtct actgctcaga 900
 aaccaccaag actgttgatg ctttagcctt gcactccagg gccctacccatg cattccctac 960
 atgactttct ggaagcctcc caactattct tgctttccctc agacagctcc cactccatg 1020
 tctctgtctca ttttagtcccg tcttcctcac cggcccttccgc ggggaacgct caagcctgg 1080
 tgaaatgctg cctcttcaatgc gaaatgc tctttcagct ctggccgcac tctgcagact 1140
 tcctatcttc gtgtgtatg tttttttt ccccccttccac tctaattggac tggccatggg 1200
 aaggatggg ggcagcagct gcttcggatc cacactgtat ctgtgtcatc cccacatggg 1260
 tcctcataaa ggattattca atggaggcat cctgacatct gtcatttag gcttcagttc 1320
 cactcccttccagg aactttgcct gtccacgag ggatgtatggg 1360

<210> 8

<211> 161

<212> PRT

<213> Homo sapiens

<220>

<221> SIGNAL

<222> (1)..(28)

<400> 8

Met	Arg	His	Asn	Trp	Thr	Pro	Asp	Leu	Ser	Pro	Leu	Trp	Val	Leu	Leu
1															15

Leu	Cys	Ala	His	Val	Val	Thr	Leu	Leu	Val	Arg	Ala	Thr	Pro	Val	Ser
															30
				20											

Gln	Thr	Thr	Thr	Ala	Ala	Thr	Ala	Ser	Val	Arg	Ser	Thr	Lys	Asp	Pro
															45
				35				40							

Cys	Pro	Ser	Gln	Pro	Pro	Val	Phe	Pro	Ala	Ala	Lys	Gln	Cys	Pro	Ala
															60
				50			55								

Leu	Glu	Val	Thr	Trp	Pro	Glu	Val	Glu	Val	Pro	Leu	Asn	Gly	Thr	Leu
															80
				65			70				75				

Ser	Leu	Ser	Cys	Val	Ala	Cys	Ser	Arg	Phe	Pro	Asn	Phe	Ser	Ile	Leu
															95
				85				90							

Tyr	Trp	Leu	Gly	Asn	Gly	Ser	Phe	Ile	Glu	His	Leu	Pro	Gly	Arg	Leu
															110
				100				105							

Trp	Glu	Gly	Ser	Thr	Ser	Arg	Glu	Arg	Gly	Ser	Thr	Gly	Trp	Ala	Glu
															125
				115			120								

Gly	Asn	Leu	Ala	Pro	His	Pro	Arg	Ser	Pro	Ala	Leu	Gln	Pro	Gln	Gln
															140
				130			135								

Ser	Thr	Ala	Ala	Gly	Leu	Arg	Leu	Ser	Thr	Gly	Pro	Ala	Ala	Ala	Gln
															160
				145			150			155					

Pro

<210> 9

<211> 7812

<212> DNA

<213> Homo sapiens

<400> 9

gtcgacggta	ccccccggaa	agatccaata	cgactcacta	tagggcggga	cagaattgat	60
ctgtgagaga	cctcatctagt	tcatacccta	gttgaccctg	gggggtggcat	gggggttagat	120

tagagatccc agtctggat cctctggaga gtaggagtcc caggagctga aggtttctgg 180
 ccactgaact ttggctaaag cagaggtgc acagctgc aagattccct ggttaaaaag 240
 taaaaatgaa atagagggtc ggggcagtgc ttcccagaa ggattgctcg gcacccctgcc 300
 ctcccagaa gcagctctgg tgctgaagag agcactgcct ccctgtgtga ctgggtgagt 360
 ccatattctc tctttgggtc tcaatttgc ctccctaat gaagggtaa gattggacta 420
 ggttaagcatc tacaaccat ttgtggtcat gagagctggg gtggggaaagg attgtcacit 480
 gaccccccac gctctgtttc taagtgtga aagagctcca ggctatgcta cgggaggaga 540
 agccagctac tgaggaaaag ccagctactg agaaaaagcg ggagtggttt accattctcc 600
 tcccccacct ttcaccagag aagaggacgt tgcacacat aaagagccag gctcaccagc 660
 tcctgacgca tgcacatcatga ccatgagaca caactggaca ccaggttaggc ctggggct 720
 cgcatgggca ggcggggtag ggtgaggtct atgaacagaa tggagcaatg ggctaaccgg 780
 gagccctcac tccaaggcaa accaccagc gcacccctggc ctgttgcctt aagaacctgg 840
 gcagatattg tagctctggc tccagctaa agcttctctg tactctgttc aataaaggc 900
 taaggggtgg gtgctgaggg gtccctcttc ccgctctgat tccctgctaa gaacccagac 960
 atctctggc tggagttaca tccttacccg ggccagccac tctgtctcca gagccgctga 1020
 cctgttaactg tcccttcctc agacccctcgc cctttgtggg tccctgctctt gtgtgcccac 1080
 gtcgtcactc tcctggtcag agccacaccc tgcctcgcaga ccaccacagc tgccactgccc 1140
 tcagttttagaa gcacaaagga cccctggccc tcccagccccc cagtgttccc agcagctaaag 1200
 cagtgtccag catttggaaagt gacccctggc gagggtggaaag tgccactgag taagaagcac 1260
 agtgggtggag ggtgggttat gggcacagag gttcccaggg tcgggttgac tcctgagcgc 1320
 cagccccctt tggcccatgtt accaccatgtt gagccagctg ggctgagcac gcaccattct 1380
 ccctccccaa cccagttgtca tgggtgcagg ctggcgcag ctcccaagat gctccctatc 1440
 aaataggaca gagaactcaa gacataagta atggtcacag gaccccccag agccttgggtt 1500
 gcagtggacc ccaaggccag cccctccacc cagagcctgc tggcctctgg ccacatctcaga 1560
 ggagcagcag ccacccagca ctgcctctgt cacctggct cccaaatgc acggctggg 1620
 cactagaaaa ggtcatcttg aggagacagg ttccagaagag gattcatcac gtgaaccaag 1680
 gaccatttccct cacattcccc gtgtttaggg cttagggcttc tcggagacaa ctgcacttct 1740
 gtaacggacg tcccccacca ggtgggtgtc agagcagttt tctaggttcc agatgcattgg 1800
 ggactggggg gagctggcag agagggcaca gcagagcagg gtaggggaag ggcctgctct 1860
 tctgaagagc taaactgtgc ctgttgcctt agatggaaacg ctgtgttat cctgtgtggc 1920
 ctgcagccgc tcccccaact tcagcattct ctactggctg ggcaatgggtt ccttcattga 1980
 gcacccccc ggcggactgt gggagggag caccaggtga gggtcgcagc agccaggtgg 2040
 gtgggaagga agccctctgc ggcctctca tgaccccttc tcccttcccg ctccagccgg 2100
 gaacgtggga gcacaggatc gcagctgtgc aaggccttgg tgctggagca gctgaccct 2160
 gcccctgcaca gcaccaactt ctccctgtgt ctctgtggacc ctgaacaggt tgccagcgt 2220
 cacgtcgccc tggccctcgc ctgggtgagg agcccaagga gaggcctcca ggaacaggag 2280
 gagctctgtc tccatatgtg gggagggaaag ggtgggtctt gccagagcag cctgtgaact 2340
 aatccccacg attccctcaag gtcagccaga caaaaaggaa cttaggttcc gggcagagga 2400
 ggttagcct gggcaaaagt gatgagatgt ccctcccttc cttggcctga tccttgcctg 2460
 ctttcacttc octaggctgg gctggggca accttgcctcc ccacccaaaga agccctgccc 2520
 tccagccaca gcagttccaca gcagcagggt taagactcag cacagggcca gcagcagcac 2580
 aacccctgacc agagcttggg tcctacctgt ctacccctggag tgaacagtcc ctgactgcct 2640
 gtaggctgcg tggatgcgc acacacccccc tccttctctg ctttgggtcc ctctctcacc 2700
 caaattcaaa ctccattccc acctacccat aaaatcacag cctccctata atgcctcctc 2760
 ctccctgcctt tctctctcca cctatccatt agcccttcttca acgtcctact cctcacactg 2820
 ctctactgct cagaaaccac caagactgtt gatgccttag cttgcactc cagggccctt 2880
 cctgcatttc ccacatgact ttctgaaagc ctcccaacta ttcttgcctt tccctgacac 2940
 ctcccaactcc catgtctctg ctcatatgtt cccgtcttcc tcaccggccc agcaggggaa 3000

cgctcaagcc tggttgaaat gctgcctt cagtgaagtc atccctttc agctctggcc 3060
 gcattctgca gacttcctat ctgcgtgctg tatgtttttt tttccccct tcactcta 3120
 ggactgttcc agggaaaggga tggggcagc agctgtttcg gatccacact gtatctgtgt 3180
 catccccaca tgggtccctca taaaggatta ttcaatggag gcacccgtac atctgttcat 3240
 ttaggcttca gttccactcc caggaacttt gcctgtccca cgagggagta tgggagagat 3300
 ggactgccac acagaagctg aagacaacac ctgcttcagg ggaacacagg cgcttgaaaa 3360
 agaaaagaga gaacagccca taatgtccc cgggagcaga ggccactaat ggagagtggg 3420
 aagagcctgg aaagatgtgg cctcaggaaa agggatgaga gaaaggaggt ggtatggaa 3480
 actcagcagg aacaaggtag gcttcaaaga gccttatattc ctcttttcc cacaccgatc 3540
 aagtcaactc agtactcaccg ggagaaaaat agactttatt tacaagtaat aacatTTAGA 3600
 aaagatccat cccccggccct taaaacccctt cccatcactc caaatcccac cccagtgc 3660
 gtctgggaa ggttagggtgt gagctgctgc tgaaggctgt cccccaaccc cactcctgag 3720
 acacaggggcc catccgtctt gggaaagagc atcccttggc aggtgctccc accaggtcag 3780
 acccagtccct ggacttcaag agtggggcc cctgctggc ccagccacca ggacagcagg 3840
 aaccaggggcc tactcctt atggccctt cttagatccag aggctaagag gaagactggc 3900
 caggcccaag gacccagcca tcaaaaccag cctcaatct ggttgtatg gagaagtgc 3960
 tttgttttaa gaaaaaaggaa ggcaaggtag ggagagcgcc cacactgtcc atqctccagg 4020
 ccccttggc cagctcccgag aaggcccgag tgaaggacca gggaccaggc cagggtgcgg 4080
 gcaggcatca ctgtctcag gggttggct actgttggcc tgggagctga gagaaggcac 4140
 tgagagggac agtagggcga ggaccaggtag acggcagcat cggggacaca ggtggggcca 4200
 ctcactggta ctggccctt agtgtttgc ctgaaagaga cacagtca 4260
 agaacttgcg atactagcct gacccactg gctgggaaga tctttctg ctccacgc 4320
 cctgtcttgg 4380
 agctctgggt getctccatg agaatgggc catctgttctt ctctcccttgg agaggagcta 4440
 ccaggacagg gacacccctt accccacacc ctccagcagc ctggcgcc 4500
 atgtacttgc 4560
 tcctgtccactt tggccatggc tggcgttgc cccatgtctt catcggtttt ccctccccca 4560
 ggcggcgctg gctgtgggg tggcaatgcg cggagaacgg cgggttccac tgcgagtgtt 4680
 gggggaaagcc ttggacaggg ctttcttga ggctccccgc cgcagaaggc tttcccttag 4740
 cttcttgggt gtgttggaga tgcgttgcg catcgactgg cgcgggtcag cctgcaagga 4800
 agggctgtca gaccggcaga cccaaatgtc cttcccaagg ccagcgtgc gtgccacgc 4860
 gtaccagcaa ggtccccca gggcgctgct tcatccccct tcagccccag cctcacctgt 4920
 ttagtagaaag ctggagctgc ttcttctgg gcctcagtag tgcgttgc 4980
 tgcgttgc 5040
 gaagaggaca gttaggca 5100
 cctctcagag ctgagtgac ctgttaatgc aacgtgcac ctgtccccct tcccaactct 5160
 gggccagatc 5220
 aaagagaggg ggaagtggc 5280
 gcctgacctg agcacagtgc tggagtaaca cccaggagcc accgcgccta cctcaggagt 5340
 tccaggggccc tggggggctt ctgggagac ccgtttgcgc tgcgtccggg tggatgcc 5400
 agtgccttcg 5460
 tccagtttc atctcctcat ctgtgtatg gcccaggctc agggaaaggct gcatgggtgg 5520
 aagaggtgg 5580
 aactctacac tgcggcaca cttatgtcg ggacccttcc tgcctacgag gtagaaagac 5640
 acaagcctcc 5700
 cagtcctgac cagattccctc tctgagctcc tgcctacccc cagggacttc acccctgagt 5760
 gcccctcc 5820
 agtgcgtatcc 5880

gcaggatgg gaggccctgc acagtgaccc caggcctcac cctggactcc agggatagca 5940
 ggcttcaga tggggggggc acactcgatt gcgcgtgcg agctctgcaa tgccgttcca 6000
 gtcatccagc tgctcaggct catcctggca agtgcccattg tagaaagtgt tccttcgt 6060
 ggaaggcagg gaagtgggaa caaatgagcc tggagtcggc aggtcacccctc ctggccctgg 6120
 catcttgcca gcctttgctg ccacctaccc cataaaacttg aagccggca caccagtctg 6180
 attcagtgcc gcaggtgcag gagtacggca cacagactat ttctatccta ggggcttgct 6240
 caccacccctc tccctggaga gggcagaaga ggtcacacgc agagactgt actacatctt 6300
 attcacctgc caaggcttgg tggccaaacac ccagaggaac aaattaagga ccggaaatta 6360
 attcccaggc gtccttggt gcccaaaggca caagagcttc caagaagagt ctggccagcc 6420
 tggccttcc agcagcccat caccgcgtga gaagggcatg gaggactccc cacagctaag 6480
 tgtcacaatt gtgctggaa tcccggggcc ttaactctgg ctaagagtgc ccccaacaca 6540
 gccagccccct agatgggcag gtaagaagg ccctgaggct gcaggaagga gggcagggtg 6600
 gagctggatg gtagcaaggaa ggccagcctt ggatttttaa aaagctttcc tctttccct 6660
 gtgccacgt ccaccccttcca gtctaatttt ggggtataatg aagtccctgt agtccccctca 6720
 cctggagggg ccccaactggc caccggcc tggaaacgc gaggcagaact gcgagtggtg 6780
 gggcggtagc caggcaagct gaggcaggct gagttgccat aatcgggaga acccaggcga 6840
 gctagagact gagtagagga ggtggctcgc aggttagctt gggaaagcagg agcagaccgc 6900
 gtgctgtaga acgttaggtt ggctgtcttgc ggtcttccca catctagctt ctgaaagaca 6960
 gagtagaatctt gttgcagtgt acagttccctg gcaactgtaca gaagctttcc attcccttcc 7020
 gaagccctca gatcccacgg cacatccatg tattcccaac tgctttgcaa aggtccctaa 7080
 agtgtgtgtc tgcaagaaat gggcccttgc gacagaagcc ctcacaaggt ggtgctgtatg 7140
 ttgtcaagac tcttctacgc attttttca tggagtctat tcataatgtt ttgaggtagg 7200
 gaatgcagag tgtttatcgg cccatttgg agatgaagtg caaagaaaata aagtgactag 7260
 ccccaaatca cactgctagg aagtatcaga gttggggcta ggcccccattt ctccctacta 7320
 gtcaggctca tcccacagcc tctgtgtcc ctcagtcacaa acttccaggcccttaccat 7380
 gttccagaac ttccttccaaac ttcttggtag cagggggcac cctaaacaca cagttcccc 7440
 ctgctgtacc agggggccccc tctcccttcc tcccaaaccct ccccttcaag atgtggaaac 7500
 aaaggcaagg gcctgcagcc tgtcaggcag tccactggc agcaacaatg ccttcagct 7560
 gcatggggca tgctgggagg cacaggatgg gctgcagctt cgccacgttc tctcccttca 7620
 ccctgcacag gtcagtgct acgcatggag agaatgctag ctttagtgcag gaggcaggga 7680
 tctaatttca gcccgcctt tttcttccaga agtgccttta accaagtac tgccctttt 7740
 aagacctctc agcttccca ctgtaacatg gactggctgc tcattccctcc ctgctcctga 7800
 ctgagtgcggc ag 7812

<210> 10

<211> 40

<212> PRT

<213> Homo sapiens

<400> 10

Thr Pro Val Ser Gln Thr Thr Ala Ala Thr Ala Ser Val Arg Ser

1 5 10 15

Thr Lys Asp Pro Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys

20 25 30

Gln Cys Pro Ala Leu Glu Val Thr

35 40

Claims:

1. An IL-18 binding protein (IL-18BP) including the amino acid sequence of SEQ ID NO:10, muteins, fused proteins, functional derivatives, active fractions, circularly permuted derivatives and mixtures thereof.
5
2. IL-18BP according to claim 1, capable of at least one of the following :
 - (i) binding to IL-18,
 - (ii) modulating the activity of IL-18,
 - 10 (iii) blocking the activity of IL-18.
3. IL-18BP selected from the group consisting of :
 - (a) polypeptides comprising any one of the amino acid sequences of SEQ ID NO:2, 4, 6, or 8;
 - 15 (b) polypeptides as defined in (a) without a leader sequence;
 - (c) muteins, fused proteins, functional derivatives, active fractions, circularly permuted derivatives and mixtures thereof of the polypeptides defined in (a) or (b); and
 - (d) viral homologues of the polypeptides defined in (a) or (b).
- 20 4. IL-18BP according to claim 3, having at least one of the following biological properties :
 - (i) binding to IL-18,
 - (ii) modulating the activity of IL-18;
 - 25 (iii) blocking the activity of IL-18.
5. IL-18BP according to any one of claims 1-4 being a non-viral protein.
6. IL-18BP according to claim 5, being a human protein.

30

7. IL-18BP according to any one of claims 1-6, having a molecular weight of about 40 kD.
8. IL-18BP according to any one of claims 1 to 7, being a fused protein.

5 9. A protein comprising an IL-18BP according to any one of claims 1-8.

10. IL-18BP according to any one of claims 1 to 9 in soluble form.
11. IL-18BP according to any one of claims 1 to 10, being non-glycosylated IL-18BP.

10 12. A DNA capable of hybridizing under stringent conditions, or which would be capable of hybridizing under stringent conditions but for the degeneracy of the genetic code to at least one of the DNA sequences shown in SEQ ID NO: 1, 3, 5 or 7, said DNA being capable of encoding an IL-18BP according to any one of claims 1 to 11.

15 13. A DNA encoding an IL-18BP according to any one of claims 1 to 11, including the amino acid sequence of SEQ ID NO:10.

20 14. A DNA encoding an IL-18BP according to any one of claims 1 to 11, including the amino acid sequence of SEQ ID NO:10 provided with a stop codon at its 3' end.

25 15. A DNA which hybridizes to the DNA of claim 13 under stringent conditions or which would be capable of hybridizing under stringent conditions but for the degeneracy of the genetic code, capable of encoding an IL-18BP according to any one of claims 1-11.

16. A DNA according to any one of claims 12 to 15 operatively linked to other DNA sequences facilitating expression, such as promoters, enhancers and the like.

30 17. A DNA according to any one of claims 12 to 16, being a genomic DNA.

18. A DNA according to any one of claims 12 to 17, being a cDNA.
19. A cDNA according to claim 18, comprising a cDNA sequence selected from the group of DNA sequences of SEQ ID NO:1, 3, 5 and 7.
5
20. A cDNA according to claims 18 or 19, being adapted for expression in a bacterial host.
10
21. A replicable expression vehicle comprising a DNA according to any one of claims 12 to 20.
15
22. A transformed host cell comprising an expression vehicle according to claim 21.
23. A transformed host cell according to claim 22, being a eukaryotic cell.
15
24. A transformed host cell according to claim 22, being a prokaryotic cell.
25. A process for the production of IL-18BP according to any one of claims 1 to 11, comprising culturing a host cell according to any one of claims 21 to 23 under conditions suitable for expression of said IL-18BP, and isolating said IL-18BP.
20
26. An antibody to IL-18BP according to any one of claims 1 to 11.
27. An antibody according to claim 26, being a polyclonal antibody.
25
28. An antibody according to claim 26, being a monoclonal antibody.
29. An antibody according to claim 26, being an anti-idiotypic antibody.
30. 30. An antibody according to claim 26, being a chimeric antibody.
30

31. An antibody according to claim 26, being a humanized antibody.
32. A process for the isolation of IL-18BP according to claim 3, comprising :
 - (a) passing a human fluid through a chromatographic column to which IL-18 is coupled,
 - (b) eluting the protein capable of binding to IL-18, and
 - (c) purifying said protein.
33. A pharmaceutical composition comprising IL-18BP according to any one of claims 1 to 11.
34. A pharmaceutical composition comprising a virus encoded homologue of IL-18BP according to any one of claims 1 to 11.
35. A pharmaceutical composition comprising a DNA encoding IL-18BP according to any one of claims 1-11.
36. Use of IL-18BP according to any one of claims 1 to 11 in the preparation of a pharmaceutical composition for the treatment of conditions requiring administration of IL-18BP.
37. Use of a virus encoded homologue of IL-18BP according to any one of claims 1 to 11 in the preparation of a pharmaceutical composition for the treatment of conditions requiring administration of IL-18BP.
38. Use of IL-18BP according to any one of claims 1 to 11 for the purification of IL-18.
39. Use of the antibodies according to any one of claims 26 to 31 in an assay for the detection of IL-18BP.

40. Use of a DNA encoding IL-18BP according to any one of claims 1 to 11 or encoding a virus encoded homologue of said IL-18BP for gene therapy.
41. Use of a DNA according to any one of claims 12 to 20 for making an IL-18BP according to any one of claims 1-11.

10

15

20

25

1/25




FIG. 1

2/25




FIG. 2

3/25




FIG. 3a

4/25




Fig. 3 B-D

5/25




Fig. 3E

6/25

IL-18Bpa; DNA sequence:

Length: 1348 December 14, 1997 15:41 Type: N Check: 2207 ..

I GAGAAGAGGA CGTTGTCACA GATAAAGAGC CAGGCTCACC AGCTCCTGAC
51 GCATGCATCA TGACCATGAG ACACAACCTGG ACACCAGACC TCAGCCCTTT
101 GTGGGTCTTG CTCCTGTGTG CCCACGTCGT CACTCTCCTG GTCAGAGCCA
151 CACCTGTCTC GCAGACCACC ACAGCTGCCA CTGCCTCAGT TAGAACAGACA
201 AAGGACCCCT GCCCCTCCCA GCCCCCAGTG TTCCCAGCAG CTAAGCAGTG
251 TCCAGCATTG GAAGTGACCT GGCCAGAGGT GGAAGTGCCA CTGAATGGAA
301 CGCTGAGCTT ATCCTGTGTG GCCTGCAGCC GCTTCCCCAA CTTCAGCATC
351 CTCTACTGGC TGGGCAATGG TTCCCTTCATT GAGCACCTCC CAGGCCGACT
401 GTGGGAGGGG AGCACCAAGCC GGGAACGTGG GAGCACAGGT ACGCAGCTGT
451 GCAAGGCCTT GGTGCTGGAG CAGCTGACCC CTGCCCTGCA CAGCACCAAC
501 TTCTCCTGTG TGCTCGTGGA CCCTGAACAG GTTGTCCAGC GTCACGTCGT
551 CCTGGCCAG CTCTGGGCTG GGCTGAGGGC AACCTTGCCC CCCACCCAAG
601 AAGCCCTGCC CTCCAGCCAC AGCAGTCCAC AGCAGCAGGG TTAAGACTCA
651 GCACAGGGCC AGCAGCAGCA CAACCTTGAC CAGAGCTTGG GTCCCTACCTG
701 TCTACCTGGA GTAACAGTC CCTGACTGCC TGTAGGCTGC GTGGATGCGC
751 AACACACCCC CTCCTTCTCT GCTTTGGTC CCTTCTCTCA CCAAATTCAA
801 ACTCCATTCC CACCTACCTA GAAAATCACA GCCTCCTTAT AATGCCTCCT
851 CCTCCTGCCA TTCTCTCTCC ACCTATCCAT TAGCCTTCCT AACGTCCTAC
901 TCCTCACACT GCTCTACTGC TCAGAAACCA CCAAGACTGT TGATGCCTTA
951 GCCTTGCACT CCAGGGCCCT ACCTGCATTT CCCACATGAC TTTCTGGAAG
1001 CCTCCCAACT ATTCTTGCTT TTCCCAGACA GCTCCCACTC CCATGTCTCT
1051 GCTCATTAG TCCCGTCTTC CTCACCGCCC CAGCAGGGGA ACGCTCAAGC
1101 CTGGTTGAAA TGCTGCCCTC TCAGTGAAGT CATCCTCTT CAGCTCTGGC
1151 CGCATTCTGC AGACTTCCTA TCTTCGTGCT GTATGTTTT TTTTCCCCC
1201 TTCACTCTAA TGGACTGTTC CAGGGAAAGGG ATGGGGCAC CAGCTGCTTC

7/25

125I GGATCCACAC TGTATCTGTG TCATCCCCAC ATGGGTCTC ATAAAGGATT

130I ATTCAATGGA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAA

(SEQ ID NO:1)

IL-18Bpa; Protein sequence:

Length: 192 June 5, 1998 13:39 Type: P Check: 3073 ..

1 MRHNWTPDLS PLWVLLCAH VVTLLVRATP VSQTTAATA SVRSTKDPCP

5I SQPPVFPAAK QCPALEVTWP EVEVPLNGTL SLSCVACSRF PNFSILYWLG

10I NGSFIEHLPG RLWEGSTSRE RGSTGTQLCK ALVLEQLTPA LHSTNFSCVL

15I VDPEQVVQRH VVLAQLWAGL RATLPPTQEA LPSSHSSPQQ QG

(SEQ ID NO:2)

Fig. 4A

IL-18BPb; DNA sequence

Length: 1038 June 19, 1998 14:10 Type: N Check: 8005 ..

1 GAGAAGAGGA CGTTGTCACA GATAAAGAGC CAGGCTCACC AGCTCCTGAC
51 GCATGCATCA TGACCATGAG ACACAACCTGG ACACCCAGACC TCAGCCCTT
101 GTGGGTCTG CTCCTGTGTG CCCACGTCGT CACTCTCCTG GTCAGAGCCA
151 CACCTGTCTC GCAGACCACC ACAGCTGCCA CTGCCTCAGT TAGAAGCACA
201 AAGGACCCCT GCCCCTCCCA GCCCCCAGTG TTCCCAGCAG CTAAGCAGTG
251 TCCACCATTG GAAGTGACCT GGCCAGAGGT GGAAGTGCCA CTGAGCTGGG
301 CTGAGGGCAA CCTTGCCCCC CACCCAAGAA GCCCTGCCCT CCAGCCACAG
351 CAGTCCACAG CAGCAGGGTT AAGACTCAGC ACAGGGCCAG CAGCAGCACA
401 ACCTTGACCA GAGCTTGGGT CCTACCTGTC TACCTGGAGT AACAGTCCC
451 TGAUTGCCTG TAGGCTGCGT GGATGCGCAA CACACCCCT CCTTCTCTGC
501 TTTGGGTCCC TTCTCTCACCC AAATTCAAAC TCCATTCCCA CCTACCTAGA
551 AAATCACAGC CTCCTTATAA TGCCTCCTCC TCCTGCCATT CTCTCTCCAC
601 CTATCCATTAA GCCTTCCTAA CGTCCTACTC CTCACACTGC TCTACTGCTC
651 AGAAACCACC AAGACTGTTG ATGCCTTAGC CTTGCACTCC AGGGCCCTAC
701 CTGCATTCC CACATGACTT TCTGGAAGCC TCCCAACTAT TCTTGCTTTT
751 CCCAGACAGC TCCCACCTCCC ATGTCTCTGC TCATTTAGTC CCGTCTTCCT
801 CACCGCCCCA GCAGGGGAAC GCTCAAGCCT GGTTGAAATG CTGCCTCTTC
851 AGTGAAGTCA TCCTCTTCA GCTCTGGCCG CATTCTGCAG ACTTCCTATC
901 TTCGTGCTGT ATGTTTTTTT TTTCCCCCTT CACTCTAACAT GACTGTTCCA
951 GGGAAAGGGAT GGGGGCACCA GCTGCTTCGG ATCCACACTG TATCTGTGTC
1001 ATCCCCACAT GGGTCCTCAT AAAGGATTAT TCAATGGA

(SEQ ID NO:3)

Fig. 5

9/25

huIL-18BPb
Clone-m7
peptide

1 MRHNWTPD LSPLWVLLC AHVVTLLVRA TPVSQTTAA TASVRSTKDP
49 CPSQPPVFPA AKQCPALEVT WPEVEVPLSW AEGNLAPHPR SPALQPQQST
99 AAGLRLSTGP AAAQP*

(SEQ ID NO:4)

Fig. 5A

10/25

hull18BPc.seq Length: 7063 July 16, 1998 19:47 Type: N Check: 9314 ..

1 GAATTCGCGG CCGCGTCGAC GCCAGAGGG CTAGGATGAG AGACAGAGGG
51 TGTGATGGTG GGTGCTGGGA AATGTACCCG ACCTTGGGGC TGGTGGCTGG
101 GGGAGTGGGT AGCCTGGAA AGGCCAGGAT GTGGACGGAC TGGTATGGCA
151 TTGAGCCTGA AGTGGTCCAA CTTGGGTTTC CCCAGTGCCT AGGAAAGTTG
201 TCCCCTGAA TGTCAGTGTG AAGGTGAAGG AGGAAGCAGA TGCCTGTTCA
251 TATGGAAACA AAGACCTGGC TGTGAAGAGG GGAGGCGGAC ACCAAAGTCC
301 TGACACTTGG GCGGGACAGA ATTGATCTGT GAGAGACTCA TCTAGTTCAT
351 ACCCTAGGTG ACCCTGGGGG TGGCATGGGG GTAGATTAGA GATCCCAGTC
401 TGGTATCCTC TGGAGAGTAG GAGTCCCAGG AGCTGAAGGT TTCTGGCCAC
451 TGAACCTTGG CTAAGCAGA GGTGTCACAG CTGCTCAAGA TTCCCTGGTT
501 AAAAAGTGAA AGTGAATAG AGGGTCGGGG CAGTGCTTTC CCAGAAGGAT
551 TGCTCGGCAT CCTGCCCTTC CCAGAACGAG CTCTGGTGC GAAGAGAGCA
601 CTGCCTCCCT GTGTGACTGG GTGAGTCCAT ATTCTCTCTT TGGGTCTCAA
651 TTTTGCCTTC CCTAATGAAG GGGTAAGATT GGACTAGGTA AGCATCTTAC
701 AACCATTTGT GGTCACTGAG GCTGGGTGG GGAAGGATTG TCACTTGACC
751 CCCCCAGCTC TGTTCTAAG TGCTGAAAGA GCTCCAGGCT ATGCTACGGG
801 AGGAGAAGCC AGCTACTGAG GAAAAGCCAG CTACTGAGAA AAAGCGGGAG
851 TGGTTTACCA TTCTCCTCCC CCACCTTCA CCAGAGAAGA GGACGTTGTC
901 ACACATAAAG AGCCAGGCTC ACCAGCTCCT GACGCATGCA TCATGACCAC
951 GAGACACAAC TGGACACCAG ACCTCAGCCC TTTGTGGTC CTGCTCCTGT
1001 GTGCCCACGT CGTCACTCTC CTGGTCAGAG CCACACCTGT CTCGCAGACC
1051 ACCACAGCTG CCACTGCCTC AGTTAGAAGC ACAAAGGACC CCTGCCCTC
1101 CCAGCCCCA GTGTTCCAG CAGCTAAGCA GTGTCCAGCA TTGGAAGTGA
1151 CCTGGCCAGA GGTGGAAGTG CCACTGAATG GAACGCTGAG CTTATCCTGT
1201 GTGGCCTGCA GCCGCTTCCC CAACTTCAGC ATCCTCTACT GGCTGGCAA

Fig. 6

11/25

1251 TGGTTCCCTTC ATTGAGCACC TCCCAGGCCG ACTGTGGGAG GGGAGCACCA
1301 GCCGGGAACG TGGGAGCACA GGTACGCAGC TGTGCAAGGC CTTGGTGCTG
1351 GAGCAGCTGA CCCCTGCCCT GCACAGCACC AACTTCTCCT GTGTGCTCGT
1401 GGACCCCTGAA CAGGTTGTCC AGCGTCACGT CGTCCTGGCC CAGCTCTGGG
1451 TGAGGAGCCC AAGGAGAGGC CTCCAGGAAC AGGAGGGAGCT CTGCTTCCAT
1501 ATGTGGGGAG GAAAGGGTGG GCTCTGCCAG AGCAGCCTGT GAACTAATGC
1551 CCAGCATTCC TCAAGGTCAg CCAGACAAAA AGGAACCTAG GTCTTGGCA
1601 GAGGAGGTGT AGCCTGGGGC AAAGTGATGA GATGTCCCTC CTTTCCTTGG
1651 CCTGATCCTT GTCTGCCCTC ACTTCCCTAG GCTGGGCTGA GGGCAACCTT
1701 GCCCCCCACC CAAGAAGCCC TGCCCTCCAG CCACAGCAGT CCACAGCAGC
1751 AGGGTTAAGA CTCAGCACAG GGCCAGCAGC AGCACAACCT TGACCAGAGC
1801 TTGGGTCCCTA CCTGTCTACC TGGAGTGAAC AGTCCCTGAC TGCGCTGTAGG
1851 CTGCGTGGAT GCGCAACACA CCCCCCTCCTT CTCTGCTTTG GGTCCCTTCT
1901 CTCACCAAAT TCAAACCTCA TTCCCACCTA CCTAGAAAAT CACAGCCTCC
1951 TTATAATGCC TCCTCCTCCT GCCATTCTCT CTCCACCTAT CCATTAGCCT
2001 TCCTAACGTC CTACTCCTCA CACTGCTCTA CTGCTCAGAA ACCACCAAGA
2051 CTGTTGATGC CTTAGCCTTG CACTCCAGGG CCCTACCTGC ATTTCCCACA
2101 TGACTTTCTG GAAGCCTCCC AACTATTCTT GCTTTCCCA GACAGCTCCC
2151 ACTCCCATGT CTCTGCTCAT TTAGTCCCGT CTTCTCACC GCCCCAGCAG
2201 GGGAACGCTC AAGCCTGGTT GAAATGCTGC CTCTTCAGTG AAGTCATCCT
2251 CTTTCAGCTC TGGCCGCATT CTGCAGACTT CCTATCTTCG TGCTGTATGT
2301 TTTTTTTTTC CCCCTTCACT CTAATGGACT GTTCCAGGGA AGGGATGGGG
2351 GCAGCAGCTG CTTCGGATCC ACACTGTATC TGTGTATCC CCACATGGGT
2401 CCTCATAAAG GATTATTCAA TGGAGGCATC CTGACATCTG TTCATTTAGG
2451 CTTCAGTTCC ACTCCCAGGA ACTTTGCCTG TCCCACGAGG GAGTATGGGA
2501 GAGATGGACT GCCACACAGA AGCTGAAGAC AACACCTGCT TCAGGGGAAC

Fig. 6A

12/25

2551 ACAGGCGCTT GAAAAAGAAA AGAGAGAAC A GCCCATAATG CTCCCCGGGA
2601 GCAGAGGCCA CTAATGGAGA GTGGGAAGAG CCTGGAAAGA TGTGGCCTCA
2651 GGAAAAGGGA TGAGAGAAAG GAGGTGGTAT GGAAGACTCA GCAGGAACAA
2701 GGTAGGCTTC AAAGAGCCTA TATTCCCTTT TTTCCCACAC CGATCAAGTC
2751 AACTCAGTAC TCACGGGAGA AAAATAGACT TTATTTACAA GTAATAACAT
2801 TTAGAAAAGA TCCATCCCCG GCCCTTAAAA ACCTTCCCAT CACTCCAAAT
2851 CCCACCCCAG TGCAAGTCTG GGGAGGTAG GGTGTGAGCT GCTGCTGAAG
2901 GCTGTCCCCC AACCCCACCTC CTGAGACACA GGGCCCATCC GTCTGGAA
2951 AGAGCATCCT CTGGCAGGTG CTCCCACCAG GTCAGACCCA GTCTGGACT
3001 TCAAGAGTGA GGGCCCCTGC TGGGCCAGC CACCAAGACA GCAGGAACCA
3051 GGGCCTACTC CTCTTATGGT CCCTTCTAGA TCCAGAGGCT AAGAGGAAGA
3101 CTGGCCAGGC CCAAGGACCC AGCCATCAAA ACCAGCCTCA AATCTGGTTG
3151 TGATGGAGAA GTGACTTGC TTTAAGAAAA AAGGAGGCAA GGTAGGGAGA
3201 GCGCCCACAC TGTCCATGCT CCAGGCCCCC TGGGCCAGCT CCGAGAAGGC
3251 GCCAGTGAAG GACCAGGGAC CAGGCCAGGG TGCAGGGCAGG CATCACTGTC
3301 TCTAGGGTT TGGCTACTGT TGGCCTGGGA GCTGAGAGAA GGCACGTGAGA
3351 GGGACAGTAG GCGGAGGACC AGGTGACGGC AGCATCGGG ACACAGGTGG
3401 GGCCACTCAC TGGTACTGGC CCTTTAGTGC TTTGCCTGAA AGAGACACAG
3451 TCACATGGCC AGATGAGAAC TTGCGATACT AGCCTGCACC CACTGGCTGG
3501 GAAGATCTCT TCCTGCTCCC ACGCCCCTGT CTGGATCCCC TCCCTTGTGA
3551 GCCCCAGGGT TATCAGTTGC TGGCTGTGCC TGAGCAGCTC TGGGTGCTCT
3601 CCATGAGAAT GGGGCCATCT GTCTTCTCTC CTTGGAGAGG AGCTACCAGG
3651 ACAGGGACAC CTCTTACCCC ACACCCCTCCA GCAGCCTGGC GTGGCCCCAT
3701 CTTGGATGCT ACTTGGTGGG GCGGTCTGGG GGGTGCCCAT GCTCTCATCG
3751 GGTTTCCCTC CCCCCATCCTG CCAGTGCCTC TACCTTGCCC TTGGCTCGAG
3801 GGGTGGCACC AATGGCGGCA GCAGTGGCGG CGCTGGCTGT GGTGGTGGCA

Fig. 6B

3851 ATGCGCGGAG AACGGCGGGT TCCACTGCGA GTGTTGGGG AAGCCTTGG
3901 CAGGGCCTTC TTTGAGGCTC CCCGCCGCAG AAGGCTGTT CCTAGCTTCT
3951 TGGGTGTGTT GAGGATGCTG AAGGCCATCG ACTGGCGCCG GTCAGCCTGC
4001 AAGGAAGGGC TGTCAGACCG GGAGACCAA TGCTGCCTTC CCAGGCCAGC
4051 GTGCTGTGCC ACGCTGTACC AGCAAGGTCC CGCCAGGGCG TCGCTTCATC
4101 CCCCTTCAGC CCCAGCCTCA CCTGTTAGT AGAACGCTGGA GCTGCTTCT
4151 TCTGGGCCTC AGTAGTGCTC TGTTGCGCC CTTCATGTCG GTCTCGGGGA
4201 GTCATGGGGC GTGGGAAACA GCTGGTGGCC TTCTTAGACT ATGGAGAAGA
4251 GGACAGTTAG GCAGACAGTA GCAAGAGGAG TCACATCTGA AGCCAGGTGT
4301 CTTGT CCTCT CAGAGCTGAG TGGACCTTGT AAGTCAACGT GCAACCTGCT
4351 CCCCTTCCC ACTCTGGCC AGATCCTTCC CTTCCAACA GTTCCCATCC
4401 ATGGGTCAAG CCCTTGGAGA GAGGGAAAGA GAGGGGGAAAG TGAGGGAAGG
4451 AGAGAGAAGG CTCCCTTAG TCCTGGTGA GCTGGCCTG ACCTGAGCAC
4501 AGTGCTGGAG TAACACCCAG GAGCCACCGC GCCTACCTCA GGAGTTCCAG
4551 GGCCCTGGTG GGGCTCTAGG GAGACCGTT TGCGCTGCTG CCGGGTGGTG
4601 ATGCCAGTGC CCTCGGCTAT CTGGATTGGC TGCATGCTGG CTCGGCGCAG
4651 GGTCTCTGG GGGCTCCAG TTTCATCTC CTCATCTGTG ATGGTGCCCA
4701 GGCTCAGGGA AGGCTGCATG GGTGGAAGAG GTGGTCAGTG GACCATAGCT
4751 GTATGGAGAT GGAGGAGGAC CTGGGGCTGT TCCAGAACTC TACACTCGCC
4801 CGACACTTAT GGTCGGGACC CTTCTGCCT ACGAGGTAGA AAGACACAAG
4851 CCTCCTTCC TGTTCTGCTT TCTACCTAAG CCCTGGCAA ATGGCACAAG
4901 CAGTGCAGTC CTGACCAGAT TCCTCTCTGA GCTCCTGCCT ACCCCCCAGGG
4951 ACTTCACCCCC TGAGTGCCT CCAGCTGTCT GTTCCACCTG GAACATGAGA
5001 AGGTCACCCCC TTCCCCCTTT CGGCCAGTCA GTGATCCAGG GCCCTAGTGC
5051 TCAGGCTAGA TCAGCAGGTG GGATTCCAAG GAAGGGCAGG GATGGGAGGC
5101 CCTGCACAGT GACCCAGGC CTCACCCCTGG ACTCCAGGG TAGCAGGTCT

5151 TCAGATGTGG GGGGCACACT CGATTGCGCT GCTGCAGCTC TGCAATGCGG
5201 TTCCAGTCAT CCAGCTGCTC AGGCTCATCC TGGCAAGTGC CCATGTAGAA
5251 GCTGTTCCCTT CCTGTGGAAG GCAGGGAAGT GGGAACAAAT GAGCCTGGAG
5301 TCGGCAGGTC ACCTCCTGGC CCTGGCATCT TGCCAGCCTT TGCTGCCACC
5351 TACCCCATAA ACTTGAAGCC CGGCACACCA GTCTGATTCA GTGCCGCAGG
5401 TGCAGGAGTA CGGCACACAG ACTATTTCTA TCCTAGGGC TTGCTCACCA
5451 CCTTCTCCCT GGAGAGGGCA GAAGAGGTCA CACGCAGAGA CTGCTACTAC
5501 ATCTTATTCA CCTGCCAAGG CTTGGTGGCC AACACCCAGA GGAACAAATT
5551 AAGGACCGGG AATTAATTCC CAGGGGCTCC CTGGTGCCCCA AAGGACAAGA
5601 GCTTCCAAGA AGAGTCTGGC CAGCCTGGCC TTTCCAGCAG CCCATCACCG
5651 CCTGAGAAGG GCATGGAGGA CTCCCCACAG CTAAGTGTCA CAATTGTGCT
5701 GGGAAATCCCG GCCCTTAAC TCTGGCTAAG AGTGCCCTCA ACACAGCCAG
5751 CCCCTAGATG GGCAGGTAAG GAAGGCCCTG AGGCTGCAGG AAGGAGGGC
5801 AGGTGGAGCT GGATGGTAGC AAGGAGGCCA GCCTGGATT TTTAAAAAGC
5851 TTTCCTCTTT TCCCTGTGCC ACGATCCACC TTCCAGTCTA ATTTTGGGGT
5901 ATAGTAAGTC CCTGTAGTCC CCTCACCTGG AGGGGCCCA CTGGACACCC
5951 CGGCCTGGGA ACGACGAGCA GAACTGCGAG TGGTGGGCG GTAGCCAGGC
6001 AAGCTGAGCA GGGCTGAGTT GCCATAATCG GGAGAACCCA GGCGAGCTAG
6051 AGACTGAGTA GAGGAGGTGG CTCGCAGGCT AGCCTGGAA GCAGGAGCAG
6101 ACCGCGTGCT GTAGAACGAT GAGTTGGCGC TGTCTGGCTC TTCCACATCT
6151 AGCTTCTGGA AGACAGAGTG AATCTGTTGC AGTGTACAGT CCCTGGCACT
6201 GTACAGAACG TTCCCATTCC CTTCCGAAGC CCTCAGATCC CACGGCACAT
6251 CCATGTATTC CCAACTGCTT TGCAAAGGTC CTTAAAGTGT GTGTCTGCAA
6301 GAAATGGGCC TTGTCGACAG AAGCCCTCAC AAGGTGGTGC TGATGTTGTC
6351 AAGACTCTTC TACGCATTTT TTTCATGGAG TCTATTCTATA ATGCTTGAG
6401 GTAGGGAATG CAGAGTGTGTT ATCGGCCAT TTTGGAGATG AAGTGCAAAG

15/25

6451 AAATAAAAGTG ACTAGCCCCA AATCACACTG CTAGGAAGTA TCAGAGCTGG
6501 GGCTAGGCCCATGTCTCCT GACTAGTCAG GCTCATCCCA CAGCCTCTGC
6551 TGTCCTCAG TCCAAACTTC CAGGGCCCTT ACCATGTTCC AGAACTTCCC
6601 CCAACTTCTT GGTAGCAGGG GGCACCCCTAA ACACACAGGT CCCCCCTGCT
6651 GTACCAGGGG CCCCCCTCTCC CCTCCTCCCA AACCTCCCCT TCAAGATGTG
6701 GAAACAAAGG CAAGGGCCTG CAGCCTGTCA GGCAGTCCAC TGGGCAGCAA
6751 CAATGCCTCT CAGCTGCATG GGGCATGCTG GGAGGCACAG GATGGGCTGC
6801 AGCTTCGCCA CGTTCTCTCC CTTCACCCCTG CACAGGCTCA GTGCTACGCA
6851 TGGAGAGAAT GCTAGCCTTA GTCAGGAGGC AGGGATCTAA TCCTAGCCCT
6901 GCCTTTTCT TCAGAAAGTGC CCTTAACCAA GTCACTGCCCTTTTAAGAC
6951 CTCTCAGCTT TCCCACGTGA ACATGGACTG GCTGCTCATC CCTCCCTGCT
7001 CCTGACTGAG TGCCCAGTGC AAAGATGCCCTTGAGAGGAA GTGGGAATTG
7051 CTGACCTGTC GAC

(SEQ ID NO:5)

IL-18BPc; Protein

Length: 197 June 5, 1998 13:41 Type: P Check: 3353 ..

1 MRHNWTPDLS PLWVLLCAH VVTLLVRATP VSQTTTAATA SVRSTKDPCP
51 SQPPVFPAAK QCPALEVTWP EVEVPLNGTL SLSCVACSRF PNFSILYWLG
101 NGSFIEHLPG RLWEGSTSRE RGSTGTQLCK ALVLEQLTPA LHSTNFSCVL
151 VDPEQVVQRH VVLAQLWVRS PRRGLQEQQEE LCFHMWGKG GLCQSSL

(SEQ ID NO:6)

Fig. 6E

16/25

IL-18BPd; DNA

Length: 1360 June 19, 1998 14:55 Type: N Check: 8757 ..

1 GCGGCCGCGT CGACCACGCA GCTAACACA GCTAACTTGA GTCTGGAGC
51 TCCTAAAGGG AAGCTTCTGG AAAGGAAGGC TCTTCAGGAC CTCTTAGGAG
101 CCAAAGAAGA GGACGTTGTC ACAGATAAAG AGCCAGGCTC ACCAGCTCCT
151 GACGCATGCA TCATGACCAT GAGACACAAC TGGACACCAAG ACCTCAGCCC
201 TTTGTGGGTC CTGCTCCTGT GTGCCACGT CGTCACTCTC CTGGTCAGAG
251 CCACACCTGT CTCGCAGACC ACCACAGCTG CCACTGCCTC AGTTAGAAGC
301 ACAAAAGGACC CCTGCCCTC CCAGCCCCCA GTGTTCCAG CAGCTAAGCA
351 GTGTCCAGCA TTGGAAGTGA CCTGGCCAGA GGTGGAAGTG CCACTGAATG
401 GAACGCTGAG CTTATCCTGT GTGGCCTGCA GCCGCTTCCC CAACTTCAGC
451 ATCCTCTACT GGCTGGCAA TGTTCCCTTC ATTGAGCACC TCCCAGGCCG
501 ACTGTGGGAG GGGAGCACCA GCCGGGAACG TGGGAGCACA GGCTGGGCTG
551 AGGGCAACCT TGCCCCCAC CCAAGAAGCC TGCCCTCCA GCCACAGCAG
601 TCCACAGCAG CAGGGTTAAG ACTCAGCACA GGGCCAGCAG CAGCACAAACC
651 TTGACCAGAG CTTGGGTCT ACCTGTCTAC CTGGAGTGAA CAGTCCCTGA
701 CTGCCCTGTAG GCTGCGTGGA TCGCAACAC ACCCCCTCCT TCTCTGCTTT
751 GGGTCCCTTC TCTCACCAAA TTCAA_aCTCC ATTCCCACCT ACCTAGAAAA
801 TCACAGCCTC CTTAT_aATGC CTCCTCCTCC TGCCATTCTC TCTCCACCTA
851 TCCATTAGCC TTCCCTAACGT CCTACTCCTC ACACTGCTCT ACTGCTCAGA
901 AACCAACCAAG ACTGTTGATG CCTTAGCCTT GCACCTCAGG GCCCTACCTG
951 CATTCCCAC ATGACTTTCT GGAAGCCTCC CAACTATTCT TGCTTTCC
1001 AGACAGCTCC CACTCCCATG TCTCTGCTCA TTTAGTCCCG TCTTCCTCAC
1051 CGCCCCAGCA GGGGAACGCT CAAGCCTGGT TGAAATGCTG CCTCTTCAGT
1101 GAAGTCATCC TCTTCAGCT CTGGCCGCA TCTGCAGACT TCCTATCTTC
1151 GTGCTGTATG TTTTTTTTTT CCCCCCTTCAC TCTAATGGAC TGTTCCAGGG

17/25

1201 AAGGGATGGG GGCAGCAGCT GCTTCGGATC CACACTGTAT CTGTGTCATC

1251 CCCACATGGG TCCTCATAAA GGATTATTCA ATGGAGGCAT CCTGACATCT

1301 GTCCATTTAG GCTTCAGTTC CACTCCCAGG AACTTTGCCT GTCCCACGAG

1351 GGAGTATGGG

(SEQ ID NO:7)

IL-18BPd; protein

Length: 161 June 5, 1998 13:40 Type: P Check: 2239 ..

1 MRHNWTPDLS PLWVLLLCAH VVTLLVRATP VSQTTAATA SVRSTKDPCP

51 SQPPVFPAAK QCPALEVTWP EVEVPLNGTL SLSCVACSRF PNFSILYWLG

101 NGSFIEHLPG RLWEGSTSRE RGSTGWAEGN LAPHPRSPAL QPQQSTAAGL

151 RLSTGPAAAQ P

(SEQ ID NO:8)

Fig. 7A

18/25

HuL-18BP gene

Length: 7812 July 15, 1998 11:55 Type: N Check: 7058 ..

1 GTCGACGGTA CCCCCGGAA AGATTTAATA CGACTCACTA TAGGGCGGGA
51 CAGAATTGAT CTGTGAGAGA CTCATCTAGT TCATACCCCTA GGTGACCCTG
101 GGGGTGGCAT GGGGGTAGAT TAGAGATCCC AGTCTGGTAT CCTCTGGAGA
151 GTAGGAGTCC CAGGAGCTGA AGGTTTCTGG CCACTGAAC TTGGCTAAAG
201 CAGAGGTGTC ACAGCTGCTC AAGATTCCCT GGTTAAAAAG TGAAAGTGAA
251 ATAGAGGGTC GGGGCAGTGC TTTCCCAGAA GGATTGCTCG GCATCCTGCC
301 CTTCCCAGAA GCAGCTCTGG TGCTGAAGAG AGCACTGCCT CCCTGTGTGA
351 CTGGGTGAGT CCATATTCTC TCTTGCGTC TCAATTTCGC CTTCCCTAAT
401 GAAGGGGTAA GATTGGACTA GGTAAGCATC TTACAACCAT TTGTGGTCAT
451 GAGAGCTGGG GTGGGGAAAGG ATTGTCACTT GACCCCCCA GCTCTGTTTC
501 TAAGTGCTGA AAGAGCTCCA GGCTATGCTA CGGGAGGAGA AGCCAGCTAC
551 TGAGGAAAAG CCAGCTACTG AGAAAAAGCG GGAGTGGTTT ACCATTCTCC
601 TCCCCCACCT TTCACCAAGAG AACAGGACGT TGTCACACAT AAAGAGCCAG
651 GCTCACCAAGC TCCTGACGCA TGCATCATGA CCATGAGACA CAACTGGACA
701 CCAGGTAGGC CTTGGGGCTA CGCATGGCA GCCGGGGTAG GGTGAGGTCT
751 ATGAACAGAA TGGAGCAATG GGCTAACCCG GAGCCTTCAC TCCAAGGCAA
801 ACCACCCAGC GCACCTGGTGTG CTGTTGCTTT AAGAACCTGG GCAGATATTG
851 TAGCTCTGGC TCCAGTCTAA AGCTTCTCTG TACTCTGGTC AATAAAGGGC
901 TAAGGGGTGG GTGCTGAGGG GTCCCTCTTC CCGCTCTGAT TCCCTGGCTA
951 GAACCCAGAC ATCTCTGGC TGGAGTTACA TCCTTACCCG GGCAGCCCAC
1001 TCTGTCTCCA GAGCCGCTGA CCTGTAACTG TCCTTCTCTC AGACCTCAGC
1051 CCTTTGTGGG TCCTGCTCCT GTGTGCCAC GTCGTCACTC TCCTGGTCAG
1101 AGCCACACCT GTCTCGCAGA CCACCACAGC TGCCACTGCC TCAGTTAGAA
1151 GCACAAAGGA CCCCTGCCCT TCCCAGCCCC CAGTGTCCCC AGCAGCTAAG

Fig. 8

1201 CAGTGTCCAG CATTGGAAGT GACCTGGCCA GAGGTGGAAG TGCCACTGAG
1251 TAAGAACAC AGTGGTGGAG GGTGGCTAT GGGCACAGAG GTTCCCAGGG
1301 TCGGGTTGAC TCCTGAGCGC CAGTCCCCTT CTGCCCATGT ACCACCAGCT
1351 GAGCCAGCTG GGCTGAGCAC GCACCATTCT CCCTCCCCAA CCCAGTGTCA
1401 TGGGTGCAGG CTTGGCGCAG CTCCAAGAT GCTCCCTATC AAATAGGACA
1451 GAGAACTCAA GACATAAGTA ATGGTCACAG GACCTCCCAG AGCCTTGGTT
1501 GCAGTGGACC CCAAGGCCAG CCCCTCCACC CAGAGCCTGC TGGCCTCTGG
1551 CCATCTCAGA GGAGCAGCAG CCATCCAGCA CTGCCTCTGT CACCTGGGCT
1601 CCCAAGTCAC CGAGGCTGGG CACTAGAAAA GGTCACTCTG AGGAGACAGG
1651 TTCAGAAGAG GATTCACTAC GTGAACCAAG GACCATT CCTCACATCCCC
1701 GTGTTAGGG CTAGGGCCTC TCGGAGACAA CTGCACTTCT GTAACGGACG
1751 TTCCCACCTA GGTGGTGTGC AGAGCAGTTC TCTAGGTTCC AGATGCATGG
1801 GGACTGGGGG GAGCTGGCAG AGAGGGCACA GCAGAGCAGG GTAGGGGAAG
1851 GGCCTGCTCT TCTGAAGAGC TAACTGCTGC CTGTGTCCCT AGATGGAACG
1901 CTGAGCTTAT CCTGTGTGGC CTGCAGCCGC TTCCCCAACT TCAGCATTCT
1951 CTACTGGCTG GGCAATGGTT CCTTCATTGA GCACCTCCCCA GGCGACTGT
2001 GGGAGGGGAG CACCAGGTGA GGGTGCAGC AGCCAGGTGG GTGGGAAGGA
2051 AGCCTCTGC GGCCTCTCA TGACCTTCC TTCCCTTCCG CTCCAGCCGG
2101 GAACGTGGGA GCACAGGTAC GCAGCTGTGC AAGGCCTTGG TGCTGGAGCA
2151 GCTGACCCCT GCCCTGCACA GCACCAACTT CTCCGTGTG CTCGTGGACC
2201 CTGAACAGGT TGTCAGCGT CACGTCGTCC TGCCCCAGCT CTGGGTGAGG
2251 AGCCCAAGGA GAGGCCTCCA GGAACAGGAG GAGCTCTGCT TCCATATGTG
2301 GGGAGGAAAG GGTGGCTCT GCCAGAGCAG CCTGTGAAC AATGCCAGC
2351 ATTCCCTCAAG GTCAGCCAGA CAAAAGGAA CTTAGGTCTT GGGCAGAGGA
2401 GGTGTAGCCT GGGGCAAAGT GATGAGATGT CCCTCCTTC CTTGGCCTGA
2451 TCCTTGCTG CCTTCACTTC CCTAGGCTGG GCTGAGGGCA ACCTTGCCCC

Fig. 8A

20/25

2501 CCACCCAAGA AGCCCTGCC CTCAGCCACA GCAGTCCACA GCAGCAGGGT
2551 TAAGACTCAG CACAGGGCCA GCAGCAGCAC AACCTTGACC AGAGCTTGGG
2601 TCCTACCTGT CTACCTGGAG TGAACAGTCC CTGACTGCCT GTAGGCTGCG
2651 TGGATGCGCA ACACACCCCCC TCCTTCTCTG CTTTGGGTCC CTTCTCTCAC
2701 CAAATTCAAA CTCCATTCCC ACCTACCTAG AAAATCACAG CCTCCTTATA
2751 ATGCCTCCTC CTCCTGCCAT TCTCTCTCCA CCTATCCATT AGCCTTCCTA
2801 ACGTCCTACT CCTCACACTG CTCTACTGCT CAGAAACAC CAAGACTGTT
2851 GATGCCTTAG CCTTGCACTC CAGGGCCCTA CCTGCATTT CCACATGACT
2901 TTCTGGAAGC CTCCCAACTA TTCTTGCTTT TCCCAGACAG CTCCCACCTCC
2951 CATGTCTCTG CTCATTTAGT CCCGTCTTCC TCACCGCCCC AGCAGGGGAA
3001 CGCTCAAGCC TGGTTGAAAT GCTGCCTTT CAGTGAAGTC ATCCTTTTC
3051 AGCTCTGGCC GCATTCTGCA GACTTCCTAT CTTCGTGCTG TATGTTTTT
3101 TTTTCCCCCT TCACTCTAAT GGACTGTTCC AGGGAAAGGA TGGGGGCAGC
3151 AGCTGCTTCG GATCCACACT GTATCTGTGT CATCCCCACA TGGGTCTC
3201 TAAAGGATTA TTCAATGGAG GCATCCTGAC ATCTGTTCAT TTAGGCTTCA
3251 GTTCCACTCC CAGGAACCTT GCCTGTCCC CGAGGGAGTA TGGGAGAGAT
3301 GGACTGCCAC ACAGAAGCTG AAGACAAACAC CTGCTTCAGG GGAACACAGG
3351 CGCTTGAAAA AGAAAAGAGA GAACAGCCC TAATGCTCCC CGGGAGCAGA
3401 GGCCACTAAT GGAGAGTGGG AAGAGCCTGG AAAGATGTGG CCTCAGGAAA
3451 AGGGATGAGA GAAAGGAGGT GGTATGGAAG ACTCAGCAGG AACAAAGGTAG
3501 GCTTCAAAGA GCCTATATTCTCTTTTCC CACACCGATC AAGTCAACTC
3551 AGTACTCACG GGAGAAAAAT AGACTTTATT TACAAGTAAT AACATTAGA
3601 AAAGATCCAT CCCCCGGCCCT TAAAAACCTT CCCATCACTC CAAATCCCAC
3651 CCCAGTGCAA GTCTGGGGAA GGTAGGGTGT GAGCTGCTGC TGAAGGCTGT
3701 CCCCCAACCC CACTCCTGAG ACACAGGGCC CATCCGTCCCT GGGAAAGAGC
3751 ATCCTCTGGC AGGTGCTCCC ACCAGGTAG ACCCAGTCCT GGACTTCAAG

Fig. 8B

21/25

3801 AGTGAGGGCC CCTGCTGGC CCAGCCACCA GGACAGCAGG AACCAGGGCC
3851 TACTCCTCTT ATGGTCCCTT CTAGATCCAG AGGCTAAGAG GAAGACTGGC
3901 CAGGCCAAG GACCCAGCCA TCAAAACCAG CCTCAAATCT GGTTGTGATG
3951 GAGAAGTGAC TTTGCTTAA GAAAAAAGGA GGCAAGGTAG GGAGAGCGCC
4001 CACACTGTCC ATGCTCCAGG CCCCCTGGC CAGCTCCGAG AAGGCCAG
4051 TGAAGGACCA GGGACCAGGC CAGGGTGCAG GCAGGCATCA CTGTCTCTAG
4101 GGGTTTGGCT ACTGTTGCC TGGGAGCTGA GAGAAGGCAC TGAGAGGGAC
4151 AGTAGGCCGA GGACCAGGTG ACGGCAGCAT CGGGGACACA GGTGGGGCCA
4201 CTCACTGGTA CTGGCCCTT AGTGCTTGC CTGAAAGAGA CACAGTCACA
4251 TGGCCAGATG AGAACTTGC ATACTAGCCT GCACCCACTG GCTGGGAAGA
4301 TCTCTTCCTG CTCCCACGCC CCTGTCTGGA TCCCCTCCCT TGTGAGCCCC
4351 AGGGTTATCA GTTGCTGGCT GTGCCTGAGC AGCTCTGGT GCTCTCCATG
4401 AGAATGGGGC CATCTGTCTT CTCTCCTTGG AGAGGAGCTA CCAGGACAGG
4451 GACACCTCTT ACCCCACACC CTCCAGCAGC CTGGCGTGGC CCCATCTTGG
4501 ATGCTACTTG GTGGGGCGGT CTGGGGGGTG CCCATGCTCT CATGGGTTT
4551 CCCTCCCCCA TCCTGCCAGT GCCTCTACCT TGCCCTTGGC TCGAGGGGTG
4601 GCACCAATGG CGGCAGCAGT GGCGCGCTG GCTGTGGTGG TGGCAATGCG
4651 CGGAGAACGG CGGGTTCCAC TGCGAGTGTG GGGGAAAGCC TTGGACAGGG
4701 CCTTCTTGA GGCTCCCCGC CGCAGAAGGC TGTTCCCTAG CTTCTGGGT
4751 GTGTTGAGGA TGCTGAAGGC CATCGACTGG CGCCGGTCAG CCTGCAAGGA
4801 AGGGCTGTCA GACCGGGAGA CCCAATGCTG CCTTCCCAGG CCAGCGTGCT
4851 GTGCCACGCT GTACCAGCAA GGTCCGCCA GGGCGTCGCT TCATCCCCCT
4901 TCAGCCCCAG CCTCACCTGT TTAGTAGAAG CTGGAGCTGC TTTCTTCTGG
4951 GCCTCAGTAG TGCTCTGTT GCGCCCTTCA TGTCGGTCTC GGGGAGTCAT
5001 GGGCGTGGG AAACAGCTGG TGGCCTCTT AGACTATGGA GAAGAGGACA
5051 GTTAGGCAGA CAGTAGCAAG AGGAGTCACA TCTGAAGCCA GGTGTCTTGT

Fig. 8C

22/25

5101 CCTCTCAGAG CTGAGTGGAC CTTGTAAGTC AACGTGCAAC CTGCTCCCT
5151 TCCCAACTCT GGGCCAGATC CTTCCCTTCC CAACAGTTCC CATCCATGGG
5201 TCAGGCCCTT GGAGAGAGGG AAAGAGAGGG GGAAGTGAGG GAAGGAGAGA
5251 GAAGGCTCCC TTTAGTCCTT GGTGAGCTGG GCCTGACCTG AGCACAGTGC
5301 TGGAGTAACA CCCAGGAGCC ACCGCGCCTA CCTCAGGAGT TCCAGGGCCC
5351 TGGTGGGGCT CTAGGGAGAC CCGTTGCGC TGCTGCCGGG TGGTGATGCC
5401 AGTGCCCTCG GCTATCTGGA TTGGCTGCAT GCTGGCTCGG CGCAGGGTCT
5451 CTTGGGGGTC TCCAGTTTC ATCTCCTCAT CTGTGATGGT GCCCAGGCTC
5501 AGGAAAGGCT GCATGGGTGG AAGAGGTGGT CAGTGGACCA TAGCTGTATG
5551 GAGATGGAGG AGGACCTGGG GCTGTTCCAG AACTCTACAC TCGCCCGACA
5601 CTTATGGTCG GGACCCTTCC TGCCTACGAG GTAGAAAGAC ACAAGCCTCC
5651 TTTCCGTTC TGCTTCTAC CTAAGCCCTG GGCAAATGGC ACAAGCAGTG
5701 CAGTCCTGAC CAGATTCTC TCTGAGCTCC TGCCTACCCC CAGGGACTTC
5751 ACCCCTGAGT GCCCTCCAGC TGTCTGTTCC ACCTGGAACA TGAGAAGGTC
5801 ACCCCTCCCC CTCTCGGCC AGTCAGTGAT CCAGGGCCCT AGTGCTCAGG
5851 CTAGATCAGC AGGTGGGATT CCAAGGAAGG GCAGGGATGG GAGGCCCTGC
5901 ACAGTACCC CAGGCCTCAC CCTGGACTCC AGGGATAGCA GGTCTTCAGA
5951 TGTGGGGGGC ACACTCGATT GCGCTGCTGC AGCTCTGCAA TGCGGTTCCA
6001 GTCATCCAGC TGCTCAGGCT CATCCTGGCA AGTCCCCATG TAGAAGCTGT
6051 TCCTTCCTGT GGAAGGCAGG GAAGTGGAA CAAATGAGCC TGGAGTCGGC
6101 AGGTACACCTC CTGGCCCTGG CATCTGCCA GCCTTGCTG CCACCTACCC
6151 CATAAAACTTG AAGCCCGGCA CACCAGTCTG ATTCAAGTGCC GCAGGTGCAG
6201 GAGTACGGCA CACAGACTAT TTCTATCCTA GGGGCTTGCT CACCACCTTC
6251 TCCCTGGAGA GGGCAGAAGA GGTACACACG AGAGACTGCT ACTACATCTT
6301 ATTCAACCTGC CAAGGCTTGG TGGCCAACAC CCAGAGGAAC AAATTAAGGA
6351 CCGGGAATTAA ATTCCCAGGG GCTCCCTGGT GCCCAAAGGA CAAGAGCTTC

Fig. 8D

6401 CAAGAAGAGT CTGGCCAGCC TGGCCTTCC AGCAGCCCAT CACCGCCTGA
6451 GAAGGGCATG GAGGACTCCC CACAGCTAAG TGTCACAATT GTGCTGGAA
6501 TCCCAGGGCCC TTAACTCTGG CTAAGAGTGC CCCCAACACA GCCAGCCCCT
6551 AGATGGGCAG GTAAGGAAGG CCCTGAGGCT GCAGGAAGGA GGGGCAGGTG
6601 GAGCTGGATG GTAGCAAGGA GGCCAGCCTT GGATTTTAA AAAGCTTTCC
6651 TCTTTCCCT GTGCCACGAT CCACCTTCCA GTCTAATTGT GGGGTATACT
6701 AAGTCCCTGT AGTCCCTCA CCTGGAGGGG CCCCCTGG ACCCCGGCC
6751 TGGGAACGAC GAGCAGAACT GCGAGTGGTG GGGCGGTAGC CAGGCAAGCT
6801 GAGCAGGGCT GAGTTGCCAT AATCGGGAGA ACCCAGGCGA GCTAGAGACT
6851 GAGTAGAGGA GGTGGCTCGC AGGCTAGCCT GGGAAAGCAGG AGCAGACCGC
6901 GTGCTGTAGA ACGATGAGTT GGCGCTGTCT GGCTTTCCA CATCTAGCTT
6951 CTGGAAGACA GAGTGAATCT GTTGCAGTGT ACAGTCCCTG GCACTGTACA
7001 GAAGCTTCCC ATTCCCTTCC GAAGCCCTCA GATCCCACGG CACATCCATG
7051 TATTCCCAAC TGCTTGCAA AGGTCTTAA AGTGTGTGTC TGCAAGAAAT
7101 GGGCCTTGTC GACAGAAGCC CTCACAAGGT GGTGCTGATG TTGTCAAGAC
7151 TCTTCTACGC ATTTTTTCA TGGAGTCTAT TCATAATGCT TTGAGGTAGG
7201 GAATGCAGAG TGTTTATCGG CCCATTTGG AGATGAAGTG CAAAGAAATA
7251 AAGTGAATG CCCCCAAATCA CACTGCTAGG AAGTATCAGA GCTGGGGCTA
7301 GGCCCCATGT CTCCTGACTA GTCAGGCTCA TCCCACAGCC TCTGCTGTCC
7351 CTCAGTCAA ACTTCCAGGG CCCTTACCAT GTTCCAGAAC TTCCCCAAC
7401 TTCTTGGTAG CAGGGGGCAC CCTAACACA CAGGTCCCCC CTGCTGTACC
7451 AGGGGGCCCCC TCTCCCTCC TCCCAAACCT CCCCTCAAG ATGTGGAAAC
7501 AAAGGCAAGG GCCTGCAGCC TGTCAGGCAG TCCACTGGC AGCAACAATG
7551 CCTCTCAGCT GCATGGGCA TGCTGGAGG CACAGGATGG GCTGCAGCTT
7601 CGCCACGTT TCCTCCCTCA CCCTGCACAG GCTCAGTGTCT ACGCATGGAG
7651 AGAATGCTAG CCTTAGTCAG GAGGCAGGGA TCTAATCCTA GCCCTGCCTT

24/25

7701 TTTCTTCAGA AGTGCCTTA ACCAAGTCAC TGCCCTTTT AAGACCTCTC

7751 AGCTTTCCA CTGTAACATG GACTGGCTGC TCATCCCTCC CTGCTCCTGA

7801 CTGAGTGCCC AG

(SEQ ID NO:9)

Fig. 8F




Fig. 9 A-D

INTERNATIONAL SEARCH REPORT

Inte onal Application No

PCT/IL 98/00379

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K14/54

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EMBL Database entry 0 00923, accession number 0 00923, Merozite Surface Protein 1 (fragment), 01/07/97 XP002087999 see abstract --- A EMBL Database entry 0 00919, accession number 0 00919, Merozite Surface Protein 1 (fragment), 01/07/97 XP002088000 see abstract ---	1 1
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the International search

15 December 1998

Date of mailing of the international search report

29/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Deffner, C-A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IL 98/00379

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EMBL Database entry HSZZ16951, accession number AA311795, Adams M.D. et al., EST182531 Jurkat T-cells VI Homo sapiens cDNA 5'end similar tp Hypothetical protein C9, 18/04/97 XP002088001 see abstract --- EMBL Database entry HSA10059, accession number AA010059, Hillier L. et al., zel6a02.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone, 02/08/96 XP002088002 see abstract --- EMBL Database entry HZZ03012, accession number g1950205, Adams M.D. et al., EST182531 Jurkat T-cells V Homo sapiens cDNA 5'end 18/04/97 XP002088003 see abstract --- EMBL Database entry HSNUMAMR, accession number g35118, Yang C.H. et al., NuMA: an unusually long coiled-coil related protein in the mammalian nucleus, 27/03/92 XP002088004 see abstract --- EMBL Database entry HSNUMAT3G, accession number g296118, Tang T.K. et al., Nuclear protein of Bovine esophageal epithelium, 31/03/93 XP002088005 see abstract --- A	12 12 12 12 12 3 3
A	EMBL Database entry Q98222, accession number Q98222, Senkevich T.G. et al., Viridae; DS-DNA enveloped viruses; poxyviridae; chordopoxvirinae, Molludcipoxviruses 01/02/1997 XP002088006 see abstract --- EMBL Database entry Q98221, accession number Q98221, Senkevich T.G. et al., Viridae; DS-DNA enveloped viruses; poxyviridae; chordopoxvirinae, Molludcipoxviruses 01/02/1997 XP002088007 see abstract ---	-/-

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/IL 98/00379

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EMBL Database entry Q17343, accession number 017343, Otsuka A.J. et al., UNC-44 Ankyrins, 01/11/1996 XP002088008 see abstract -----	3